fluorouracil has been researched along with Anal Cancer in 425 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Excerpt | Relevance | Reference |
---|---|---|
"Although chemoradiation using 5-fluorouracil (5-FU) and mitomycin-C (MMC) is the standard of care in the treatment of anal cancer, many patients are unable to tolerate MMC." | 9.15 | Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). ( Benson, AB; Catalano, PJ; Chakravarthy, AB; Mansour, EG; Martenson, JA; Mondschein, JK; Talamonti, MS; Wagner, H, 2011) |
"A prospective clinical trial was performed to assess the response and toxicity associated with the use of high dose radiation therapy, 5-fluorouracil, and cisplatin in patients with anal cancer." | 9.08 | Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. ( Benson, AB; Kaplan, EH; Lipsitz, SR; Mansour, EG; Martenson, JA; Otteman, LA; Schuchter, LM; Talamonti, MS; Wagner, H, 1996) |
"Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin, with surgery reserved for those who fall on this regimen." | 9.08 | Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. ( , 1996) |
"Standard treatment for locally advanced anal cancer is chemoradiotherapy with mitomycin C and fluorouracil." | 8.95 | Capecitabine in locally advanced anal cancer, do we need randomised evidence? ( Chong, LC; Healey, T; Michele, T; Price, TJ, 2017) |
"To obtain safety and preliminary efficacy data of the combination of ADXS11-001, live attenuated Listeria monocytogenes bacterium, with mitomycin, 5-fluorouracil (5-FU), and intensity modulated radiation therapy in locally advanced anal cancer." | 7.88 | Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer. ( Barth, P; DiPetrillo, TA; Klipfel, A; Leonard, KL; Mantripragada, K; Oldenburg, N; Perez, K; Rajdev, L; Rosati, K; Roth, L; Safran, H; Schechter, S; Shah, N; Sheng, IY; Vrees, M, 2018) |
"Fulminant myocarditis is a rare but potentially life-threatening illness caused by 5-fluorouracil cardiotoxicity." | 7.83 | Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil. ( Amraotkar, AR; DeFilippis, AP; Grubb, KJ; Pachika, A, 2016) |
"Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 7.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
"Myocardial ischemia induced by 5-fluorouracil (5-FU) is a relatively rare, but potentially serious, occurrence." | 7.70 | Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. ( Akpek, G; Hartshorn, KL, 1999) |
"The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 6.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
"Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM)." | 6.78 | Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. ( de Vries, HJ; Dijkgraaf, MG; Prins, JM; Richel, O; van Noesel, CJ, 2013) |
"To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)." | 6.74 | Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). ( Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009) |
"Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 5.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
"Anal cancer is the first tumour in which chemoradiotherapy with the intent of organ preservation has largely replaced surgery and is an interesting model of modern multimodal oncological treatment." | 5.33 | Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. ( Arponen, P; Blomqvist, C; Saarilahti, K; Tenhunen, M; Vaalavirta, L, 2006) |
"To measure co-expression of EGFR and Ki67 proteins in pretreatment tumor biopsies of anal cancer patients enrolled on NRG Oncology RTOG 9811, a phase III trial comparing 5-fluorouracil/mitomycin-C/radiation therapy (Arm A) versus 5-fluorouracil/cisplatin/radiation therapy (Arm B), and to correlate expression with clinical outcome." | 5.24 | Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. ( Ajani, JA; Becker, MJ; Berk, LB; Crane, CH; Doll, CM; Ellis, RJ; Grisell, DL; Guha, C; Ho, CK; Kachnic, LA; Klimowicz, A; Kornaga, EN; Lees-Miller, SP; Magliocco, AM; Marsa, GW; Moughan, J; Okawara, GS; Roof, KS; Sperduto, PW, 2017) |
"Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status and normal blood and renal function, were treated with capecitabine 825 mg/m(2) bid during radiotherapy associated with a single dose of mitomycin 15 mg/m(2) on day 1." | 5.22 | Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. ( Alex, AK; Bariani, G; Braghirolli, MI; Hoff, PM; Moniz, CM; Nahas, C; Oliveira, SC; Riechelmann, R, 2016) |
"To evaluate toxicity, local control, and survival of anal cancer patients treated with helical tomotherapy (HT) and concurrent 5-fluorouracil and mitomycin-C (5FU/MMC)." | 5.20 | Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer. ( Doll, C; Field, C; Ghosh, S; Joseph, K; Mulder, K; Nijjar, T; Nijjar, Y; Schiller, D; Severin, D; Syme, A; Tankel, K; Usmani, N; Warkentin, H; Wong, C, 2015) |
"Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
"The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50." | 5.17 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. ( Begum, R; Cunningham, D; Essapen, S; Falk, S; Glynne-Jones, R; Gollins, S; James, RD; Kadalayil, L; Ledermann, J; Leslie, M; Maughan, T; McDonald, A; Meadows, HM; Myint, AS; Saunders, MP; Sebag-Montefiore, D; Wilson, C, 2013) |
"The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin." | 5.17 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013) |
"A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811." | 5.17 | RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013) |
"The United Kingdom Coordinating Committee on Cancer Research anal cancer trial demonstrated the benefit of combined modality treatment (CMT) using radiotherapy (RT), infusional 5-fluorouracil, and mitomycin C over RT alone." | 5.15 | "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). ( Adams, R; Glynne-Jones, R; Gollins, S; James, R; Jitlal, M; McDonald, A; Meadows, HM; Northover, JM; Sebag-Montefiore, D, 2011) |
"Although chemoradiation using 5-fluorouracil (5-FU) and mitomycin-C (MMC) is the standard of care in the treatment of anal cancer, many patients are unable to tolerate MMC." | 5.15 | Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). ( Benson, AB; Catalano, PJ; Chakravarthy, AB; Mansour, EG; Martenson, JA; Mondschein, JK; Talamonti, MS; Wagner, H, 2011) |
"Radiation Therapy Oncology Group (RTOG) 92-08 began as a single arm, Phase II trial for patients with anal cancer consisting of radiation (RT) + 5-flourouracil + mitomycin-C with a mandatory 2-week break and was amended after completion to evaluate the same treatment regimen without a treatment break." | 5.13 | Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. ( Garcia, M; John, M; Konski, A; Krieg, R; Myerson, R; Pinover, W; Willett, C, 2008) |
"Patients with previously untreated anal canal cancers with T3 or T4 tumors and/or extensive nodal involvement (bulky N2 or N3) received two 28-day cycles of induction treatment with infusional FU plus cisplatin followed by two 28-day cycles of FU plus mitomycin C with concurrent split-course radiation." | 5.13 | Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( Budinger, S; Colacchio, TA; Day, JM; Ellerton, J; Goldberg, RM; Hopkins, J; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Shank, B; Tepper, J; Valone, F, 2008) |
"A prospective clinical trial was performed to assess the response and toxicity associated with the use of high dose radiation therapy, 5-fluorouracil, and cisplatin in patients with anal cancer." | 5.08 | Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. ( Benson, AB; Kaplan, EH; Lipsitz, SR; Mansour, EG; Martenson, JA; Otteman, LA; Schuchter, LM; Talamonti, MS; Wagner, H, 1996) |
"Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin, with surgery reserved for those who fall on this regimen." | 5.08 | Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. ( , 1996) |
"Concomitant external-beam radiochemotherapy (5-fluorouracil-mitomycin C) has become the standard of care in anal cancer since the '90s." | 5.01 | Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). ( Ajani, JA; Bosset, JF; Chakravarthy, AB; Christiaens, M; Collette, L; Glynne-Jones, R; Hannoun-Levi, JM; Haustermans, K; Konski, AA; Maingon, P; Matzinger, O; Meadows, H; Northover, J; Peiffert, D; Puyraveau, M; Rivin Del Campo, E; Winter, KA, 2019) |
"Since the initial development of 5-fluorouracil and mitomycin as a standard of care platform for definitive anal cancer chemoradiotherapy, multiple studies have evaluated the optimal chemotherapy regimen, and radiotherapy technique." | 5.01 | Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. ( A Goodman, K; Ladbury, C; Olsen, JR; Schefter, TE, 2019) |
"Standard treatment for locally advanced anal cancer is chemoradiotherapy with mitomycin C and fluorouracil." | 4.95 | Capecitabine in locally advanced anal cancer, do we need randomised evidence? ( Chong, LC; Healey, T; Michele, T; Price, TJ, 2017) |
"Standard treatment for anal canal cancer is definitive radiochemotherapy (RCT) with 5-fluorouracil plus mitomycin C." | 4.86 | [Radiochemotherapy for locally advanced anal cancer]. ( Rödel, C, 2010) |
"The contemporary treatment of anal cancer is combined-modality therapy with radiation therapy, fluorouracil, and mitomycin." | 4.85 | Intensity-modulated radiation therapy for anal cancer. ( Czito, BG; Meyer, JJ; Pepek, JM; Willett, CG; Yoo, S, 2009) |
"Consecutive patients with locally advanced (T2 ≥ 4 cm-T4 or N+) anal cancer scheduled for two cycles of concomitant 5-fluorouracil and mitomycin C chemotherapy were selected from an institutional database (n = 106)." | 4.02 | Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. ( Johnsson, A; Nilsson, MP; Scherman, J, 2021) |
"Between 2000 and 2015, a total of 112 consecutive patients with UICC stage I-IV anal cancer received chemoradiotherapy with 5‑fluororuracil and mitomycin C (CRT)." | 3.91 | Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. ( Fietkau, R; Grützmann, R; Matzel, KE; Ott, OJ; Raptis, D; Schmidt, M; Schneider, I; Semrau, S; Strnad, V; Uter, W, 2019) |
"Definitive chemoradiation with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) is an effective treatment for localized anal cancer, but it is associated with significant acute long-term treatment-related toxicity." | 3.91 | Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. ( Adams, J; Allen, JN; Baglini, C; Ben-Josef, E; Blaszkowsky, LS; Clark, JW; DeLaney, TF; Drapek, LC; Hong, TS; Jiang, W; Metz, JM; Murphy, JE; Parikh, AR; Plastaras, JP; Ryan, DP; Wo, JY; Yeap, BY, 2019) |
"During a regular MR control, the patient developed anaphylactic reaction to Gadolinium, and after that a rectosigmoid ischemia with total necrosis of the posterior rectal wall was diagnosed and surgically treated with Hartmann procedure." | 3.91 | Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication. ( Calvisi, G; Carlei, F; Di Sibio, A; Di Staso, M; Giuliani, A; Lombardi, L; Marchese, M; Romano, L; Romanzi, F; Schietroma, M, 2019) |
" We investigated the prognostic role of baseline hemoglobin (Hb) in a cohort of anal cancer patients submitted to CT-RT with 5-fluorouracil and mitomycin C." | 3.88 | The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. ( Andrikou, K; Arcadipane, F; Casadei Gardini, A; Casadei, C; Cascinu, S; Cassoni, P; Fornaro, L; Franco, P; Iorio, GC; Martini, S; Mistrangelo, M; Montagnani, F; Ricardi, U; Scartozzi, M, 2018) |
"To obtain safety and preliminary efficacy data of the combination of ADXS11-001, live attenuated Listeria monocytogenes bacterium, with mitomycin, 5-fluorouracil (5-FU), and intensity modulated radiation therapy in locally advanced anal cancer." | 3.88 | Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer. ( Barth, P; DiPetrillo, TA; Klipfel, A; Leonard, KL; Mantripragada, K; Oldenburg, N; Perez, K; Rajdev, L; Rosati, K; Roth, L; Safran, H; Schechter, S; Shah, N; Sheng, IY; Vrees, M, 2018) |
"NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer." | 3.85 | Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. ( Abitbol, A; Chang, A; Chen, Y; Crane, CH; Doncals, DE; Fisher, B; Johnson, D; Kachnic, L; Michalski, J; Moughan, J; Myerson, R; Narayan, S; Olsen, JR; Schefter, TE, 2017) |
"Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C." | 3.85 | Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017) |
"The cohort included 45 patients with nonmetastatic anal cancer who underwent FDG-PET imaging prior to definitive chemoradiation with mitomycin-C and 5-fluorouracil." | 3.83 | Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. ( Allen, JN; Blaszkowsky, LS; Drapek, LC; Hong, TS; Jee, KW; Lee, LK; Murphy, JE; Niemierko, A; Rose, BS; Wang, Y; Wo, JY, 2016) |
"Fulminant myocarditis is a rare but potentially life-threatening illness caused by 5-fluorouracil cardiotoxicity." | 3.83 | Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil. ( Amraotkar, AR; DeFilippis, AP; Grubb, KJ; Pachika, A, 2016) |
"Concomitant chemoradiotherapy of 5-fluorouracil and cisplatin with radiotherapy is a highly effective and well-tolerated treatment of anal cancer." | 3.81 | Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2015) |
"Concurrent chemoradiotherapy with 5-fluorouracil (5-FU) and mitomycin-C (MMC) is standard treatment for anal cancer." | 3.81 | Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. ( Aleshin, A; Goldman, K; Lien, WW; Rao, AR; White, EC, 2015) |
"Between 1976 and 2008, 116 patients with T2 node-negative anal cancer were treated curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) (n=68) incorporating mitomycin C and 5-fluorouracil." | 3.79 | Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. ( Allal, AS; Betz, M; Bieri, S; Ris, F; Roche, B; Roth, AD; Zilli, T, 2013) |
"To investigate the prognostic value of epidermal growth factor receptor (EGFR) expression in pretreatment tumor biopsy specimens of patients with anal cancer treated with concurrent 5-fluorouracil and mitomycin C-based chemoradiation therapy (CRT)." | 3.79 | Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy. ( Diallo-Georgiopoulou, M; Distel, L; Falk, S; Fraunholz, I; Kohler, D; Rödel, C; Rödel, F, 2013) |
"Between 1976 and 2008, 146 patients with T1 (n=29) or T2 (n=117) N0 M0 anal cancer were treated curatively by RT alone (n=71) or by combined chemoradiotherapy (CRT) (n=75) consisting of mitomycin C±5-fluorouracil." | 3.78 | Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? ( Allal, AS; Gervaz, P; Ozsahin, M; Roth, AD; Schick, U; Zilli, T, 2012) |
"To investigate the prognostic value of survivin expression in pretreatment specimens from patients with anal cancer treated with concurrent 5-FU and mitomycin C-based chemoradiation (CRT)." | 3.78 | High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. ( Distel, L; Falk, S; Fraunholz, I; Kohler, D; Rave-Fränk, M; Rödel, C; Rödel, F, 2012) |
"Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 3.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
"For a woman with poorly-differentiated anal canal adenocarcinoma in acknowledgment of metastasis to right inguinal lymph node, we gave radiotherapy combined with capecitabine as chemotherapy." | 3.77 | [Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node]. ( Ide, Y; Makino, S; Murata, K, 2011) |
"The current standard of care for the treatment of anal cancer as demonstrated by all of the completed phase 3 clinical trials remains 5-FU and mitomycin C in combination with radiation therapy." | 3.72 | Recent clinical trials summary. ( Bleday, R; Nathanson, DR; Thomas, CR, 2004) |
"Myocardial ischemia induced by 5-fluorouracil (5-FU) is a relatively rare, but potentially serious, occurrence." | 3.70 | Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. ( Akpek, G; Hartshorn, KL, 1999) |
"Between 1982 and 1992, 139 patients with epidermoid carcinoma of the anal canal were treated by radiation and chemotherapy with 5-fluorouracil (5-Fu) and mitomycin C (MMC)." | 3.69 | [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. ( Budach, V; Döker, R; Grabenbauer, GG; Huber, K; Hültenschmidt, B; Hutter, M; Kuhne-Velte, HJ; Panzer, M; Rühl, U; Wendt, T, 1994) |
"Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C." | 3.69 | Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994) |
"Acute myocardial infarction was observed in two patients receiving standard intravenous doses of 5-fluorouracil (5-FU)-based chemotherapy." | 3.68 | Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. ( Esparaz, B; Green, D; Kies, M; Kuzel, T, 1990) |
"Twenty-four patients with carcinoma of the anus were treated with a combined regimen of external irradiation (50 Gy) and mitomycin C and 5-fluorouracil." | 3.67 | Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy. ( Flokkmann, A; Fosså, SD; Guldvog, I; Haffner, J; Karlsen, KO; Tveit, KM, 1989) |
"Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus." | 3.67 | Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986) |
"Anal squamous cell carcinoma (ASCC) is a rare tumor; it accounts for about 2% of gastrointestinal tumors." | 3.11 | Capecitabine in the treatment of anal squamous cell carcinoma. ( Radka, L; Zdeňka, P, 2022) |
"Anal squamous cell carcinoma (ASqCC) is a rare malignancy, traditionally treated with combined chemoradiation, with a continuous infusion of 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.01 | Comparison of intravenous 5-Fluorouracil with Oral Capecitabine in the Treatment of Anal Squamous Cell Carcinoma Using Modern Radiation Techniques. ( Ben David, MA; Grinberg, V; Hod, K; Kalmus, Y; Levin, D; Lipski, Y; Pfeffer, RM; Schlosser, S; Zalmanov, S, 2023) |
"Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection." | 2.84 | Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. ( Aboulafia, D; Fitzgerald, TJ; Henry, DH; Kachnic, L; Lee, JY; Mitsuyasu, R; Palefsky, J; Rajdev, L; Ratner, L; Sparano, JA; Wachsman, W, 2017) |
"Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after sphincter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human papilloma virus infection." | 2.84 | Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). ( Armstrong, KI; Benson, AB; El-Rayes, BF; Fitzgerald, TJ; Garg, MK; Kalnicki, S; Mitchell, EP; Moriarty, DJ; Mulcahy, MF; Nabbout, NH; Onitilo, AA; Palefsky, J; Sparano, JA; Whittington, R; Zhao, F, 2017) |
"Anal cancer is considered a rare tumor, accounting for 6 % of digestive cancers and about 2000 new cases per year in France." | 2.82 | [Anal cancer: Focus on current treatment and future perspective]. ( Combet-Curt, V; Delhiat, AC; Vendrely, V, 2022) |
" Conclusions HT with daily IGRT is efficacious and safe in the treatment of anal canal cancer patients, and is considered in our department standard of care in this clinical setting." | 2.82 | Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. ( Bouchaab, H; Bourhis, J; De Bari, B; Hanhloser, D; Jumeau, R; Matzinger, O; Mirimanoff, RO; Ozsahin, EM; Troussier, I; Vallet, V; Wagner, AD, 2016) |
"The treatment for squamous cell carcinoma of the anus changed dramatically during the study period." | 2.80 | The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus. ( Aravani, A; Downing, A; Finan, PJ; Lawton, S; Morris, EJ; Sebag-Montefiore, D; Thomas, JD, 2015) |
"The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 2.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
"Chemoradiotherapy (CRT) for squamous cell carcinoma of the anus (SCCA) may cause significant toxicity, and concerns exist about its tolerability in the elderly." | 2.79 | Impact of advancing age on treatment and outcomes in anal cancer. ( Chander, S; Chu, J; Foo, M; Heriot, A; Lee, MT; Leong, T; Link, E; Michael, M; Ngan, SY; Tomaszewski, JM; Tran, PK, 2014) |
"Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM)." | 2.78 | Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. ( de Vries, HJ; Dijkgraaf, MG; Prins, JM; Richel, O; van Noesel, CJ, 2013) |
"Fifty-eight anal cancer patients were treated with concurrent chemotherapy and IMRT." | 2.78 | Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy. ( Beriwal, S; DeFoe, SG; Heron, DE; Kabolizadeh, P, 2013) |
"The trial was prematurely stopped after the declaration of 15 serious adverse events (SAEs) in 14 out of 16 patients." | 2.78 | Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. ( Azria, D; Becouarn, Y; Conroy, T; Delarochefordiere, A; Deutsch, E; Ezra, P; Juzyna, B; Lemanski, C; Levy, A; Malekzadeh, K; Malka, D; Martel-Lafay, I; Miglianico, L; Paris, E; Pignon, JP; Rio, E, 2013) |
" Maintenance chemotherapy started 4-8 weeks later, three courses repeated every 21 days, using 5-FU/CDDP doses above, with MMC reduced to 7 mg/m(2) and administered with the first and third cycles." | 2.77 | Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. ( Cunningham, D; Davidson, N; Glynne-Jones, R; Grieve, R; Hurman, DC; Levine, E; Meadows, HM; Plowman, PN; Sebag-Montefiore, D, 2012) |
"The first UKCCCR Anal Cancer Trial (1996) demonstrated the benefit of chemoradiation over radiotherapy (RT) alone for treating epidermoid anal cancer, and it became the standard treatment." | 2.75 | Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). ( Glynne-Jones, R; James, R; Jitlal, M; Ledermann, J; Meadows, H; Northover, J; Sebag-Montefiore, D; Wan, S, 2010) |
"To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)." | 2.74 | Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). ( Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009) |
"These tumours are assessed as rectal cancer using immunohistochemical and radiological tests, and certain criteria (localisation, relationship with neighbouring structures) have to be fulfilled to make the diagnosis." | 2.72 | Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations. ( Astaras, C; Bornand, A; Koessler, T, 2021) |
"Patients were randomly assigned to undergo chemotherapy with 5-fluorouracil (5-FU) and mitomycin-C combined with radiotherapy with (arm A: 24 patients) or without ICHT (arm B: 25 patients)." | 2.71 | Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. ( Dardoufas, C; Gennatas, C; Kouloulias, V; Kouvaris, J; Papavasiliou, C; Plataniotis, G; Uzunoglu, N; Vlahos, L, 2005) |
"An alternative approach to anal Bowen's disease was investigated." | 2.71 | Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. ( Arnold, LK; Foote, JE; Graham, BD; Jetmore, AB, 2005) |
"In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol." | 2.71 | Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. ( Charnley, N; Chesser, P; Choudhury, A; Cooper, RA; Sebag-Montefiore, D, 2005) |
"Patients with residual tumor on posttreatment biopsy were treated with a salvage regimen that consisted of additional pelvic RT (9 Gy), 5-FU, and cisplatin (100 mg/m2)." | 2.68 | Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. ( Coia, L; Doggett, S; Flam, M; John, M; Kerman, H; Murray, K; Myerson, R; Pajak, TF; Petrelli, N; Quivey, J; Rotman, M, 1996) |
"The patients had T3-4NO-3 or T1-2N1-3 anal cancer." | 2.68 | Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro ( Bartelink, H; Bosset, JF; Eschwege, F; Gonzalez, DG; Peiffert, D; Pierart, M; Roelofsen, F; Rougier, P; van Glabbeke, M, 1997) |
"Mitomycin's role in anal cancer is being evaluated in a randomized clinical trial by the Radiation Therapy Oncology Group." | 2.67 | Mitomycin in anal canal carcinoma. ( Catton, CN; Cummings, BJ; Keane, TJ; O'Sullivan, B; Wong, CS, 1993) |
"Dinitrochlorobenzene was used to eradicate lesions that had been resistant to treatment with podophyllum resin." | 2.64 | Condyloma. A new epidemic. ( Meiselbaugh, DM; Moore, GE; Norton, LW, 1978) |
" Management of these adverse effects is reviewed, as are future directions in anal cancer treatment and their impact on toxicity." | 2.55 | Evolution and Management of Treatment-Related Toxicity in Anal Cancer. ( Czito, BG; Kachnic, LA; Ludmir, EB, 2017) |
" The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT." | 2.53 | Advances in the Management of Anal Cancer. ( Goodman, KA; Julie, DR, 2016) |
"The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage." | 2.52 | Anal cancer treatment: current status and future perspectives. ( Abdayem, P; Antoun, J; Ghosn, M; Kourie, HR; Nasr, D, 2015) |
"Although anal canal squamous cell carcinoma is rare, the general practitioner should consider this diagnosis in a patient with persistent lower abdominal symptoms." | 2.47 | [Management of anal canal carcinoma]. ( Betz, M; Cochet, S; George, AC; Roth, A; Thang, NN, 2011) |
"We report a case with perianal squamous cell carcinoma, which showed a complete response more than five years after chemoradiotherapy." | 2.47 | [A case of perianal squamous cell carcinoma attaining a complete response over five years with chemoradiotherapy]. ( Imada, S; Ishikawa, O; Kishi, K; Miyashiro, I; Motoori, M; Nishiyama, K; Noura, S; Ohue, M; Shingai, T; Yano, M, 2011) |
"The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cisplatin." | 2.44 | Current treatment for localized anal carcinoma. ( Ajani, JA; Crane, CH; Das, P, 2007) |
"Case 2: A 74-year-old female with anal squamous cell carcinoma Stage II was treated by chemoradiotherapy with tegafur/uracil, external irradiation (30 Gy) and interstitial irradiation (24 Gy)." | 2.42 | [Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Sawamura, T; Takeda, Y; Takeno, A; Tsujinaka, T, 2004) |
"During the past two decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumours; so far, it remains one of the few carcinomas of the gastrointestinal tract which are curable without the need for definitive surgery." | 2.42 | Chemotherapeutic options in the management of anal cancer. ( Allal, AS; Gervaz, P; Morel, P; Roth, A, 2004) |
"Mitomycin C and 5 FU were delivered on weeks 1 and 5 of the irradiation." | 2.41 | [Radiochemotherapy in anal canal epidermoid cancer]. ( Peiffert, D, 2000) |
"The majority of these cases were anal cancers with proximal extension into the rectum and were excluded." | 2.40 | Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature. ( Francis, B; Juturi, JV; Koontz, PW; Wilkes, JD, 1999) |
"Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma." | 2.40 | Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999) |
" In this study, we report the safety and efficacy of cetuximab (an epidermal growth factor receptor inhibitor) in combination with 5-FU plus irinotecan based chemotherapy." | 1.91 | Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. ( Boige, V; Boilève, A; Cervantes, B; Ducreux, M; Hollebecque, A; Malka, D; Smolenschi, C; Valery, M, 2023) |
"Anal cancer is a rare form of gastrointestinal malignancy, and treatment is often confined to specialist centres." | 1.91 | Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. ( Elmasry, A; Giridharan, S; Patel, C, 2023) |
"International guidelines regarding the treatment of squamous cell carcinoma of the anus (SCCA) recommend intensity-modulated radiotherapy (IMRT) combined with mitomycin-based chemotherapy (CT)." | 1.91 | Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. ( Baba-Hamed, N; Crehange, G; Diaz, O; Drouet, F; Hautefeuille, V; Hummelsberger, M; Larrouy, A; LE Malicot, K; Lemanski, C; Lepage, C; Lievre, A; Menager-Tabourel, E; Minsat, M; Mornex, F; Peiffert, D; Pommier, P; Quero, L; Regnault, P; Rivin Del Campo, E; Ronchin, P; Saint, A; Tougeron, D; Vendrely, V; Zasadny, X, 2023) |
" Gastrointestinal toxicity was retrospectively graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5." | 1.72 | Dosimetric and Clinical Predictors for Acute and Late Gastrointestinal Toxicity Following Chemoradiotherapy of Locally Advanced Anal Cancer. ( Gunnlaugsson, A; Johnsson, A; Nilsson, MP; Scherman, J, 2022) |
"Although rare, the rate of squamous cell carcinoma of the anus (SCCA) is rising globally." | 1.72 | Current treatment and future directions in the management of anal cancer. ( Eng, C; Hong, TS; Kachnic, LA; Ludmir, EB; Messick, CA; Tchelebi, LT; Zaorsky, NG, 2022) |
"Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity." | 1.72 | Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. ( Bednarski, BK; Chang, GJ; Das, P; Delclos, ME; Eng, C; Holliday, EB; Jennings, K; Johnson, B; Koay, EJ; Koong, AC; Ludmir, EB; Messick, CA; Minsky, BD; Morris, VK; Rodriguez-Bigas, MA; Skibber, JM; Smith, GL; Taniguchi, C; Tillman, MM; You, YN, 2022) |
"Novel toxicity metrics that account for all adverse event (AE) grades and the frequency of may enhance toxicity reporting in clinical trials." | 1.72 | Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. ( Ajani, J; Augspurger, ME; Crane, CH; Doncals, DE; Garg, MK; Kachnic, LA; Kharofa, JR; Kim, H; Lee, RJ; Mamon, HJ; Meyer, JE; Moughan, J; Narayan, S; Okawara, GS; Schefter, TE; Schwartz, MA; Swanson, TA; Yothers, G; Zaki, BI, 2022) |
"Twenty-five patients with squamous cell carcinoma of the anal canal were treated at our centre from 2012 to 2019 using IMRT based chemoradiation." | 1.72 | Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience. ( Ram, TS; Ramireddy, JK; Sathyamurthy, A; Singh, K, 2022) |
"Anal cancer is a rare disease that has doubled in incidence over the last four decades." | 1.62 | Molecular and genomic characterisation of a panel of human anal cancer cell lines. ( Behrenbruch, CC; Bernardi, MP; Chittleborough, TJ; Di Costanzo, N; Guerra, GR; Hawkes, D; Haynes, NM; Heriot, AG; Kong, JC; Liu, DS; Lupat, R; Millen, RM; Mitchell, C; Ngan, SY; Phillips, WA; Ramsay, RG; Read, M; Roth, S; Sampurno, S; Sia, J; Teh, J; Tothill, RW; Xu, H; Yu, J, 2021) |
"Anal squamous cell carcinoma has rarely been reported in the setting of ulcerative colitis." | 1.62 | Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols? ( Click, B; Hull, TL; Lightner, AL; McMichael, J; Regueiro, M; Steele, SR; Vaidya, P, 2021) |
"Definitive chemoradiation for anal cancer is effective but may be associated with toxic effects, and some patients may not be able to complete the planned treatment." | 1.56 | Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma. ( Booth, CM; Brogly, SB; Hanna, TP; Kalyvas, M; Ko, G; Li, W; Patel, SV; Raphael, MJ, 2020) |
"Among patients with anal cancer, chemoradiotherapy is often associated with toxicities that diminish quality of life." | 1.56 | Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. ( Abi Jaoude, J; Colbert, LE; Das, P; El Alam, MB; Holliday, EB; Klopp, AH; Koay, EJ; Kouzy, R; Lin, D; Minsky, BD; Taniguchi, CM, 2020) |
"Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0." | 1.56 | Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020) |
"Metastatic squamous cell carcinomas (SCC) of the anal canal are rare and there is no international consensus on their second-line management." | 1.51 | Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. ( Benezery, K; Cavaglione, G; Evesque, L; Falk, AT; Francois, E; Montagne, L; Saint, A, 2019) |
"For 70 women with anal cancer treated at our department, acute and chronic side effects and quality of life (QoL) were evaluated with questionnaires using the Common Terminology Criteria for Adverse Events (CTCAE v." | 1.51 | Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. ( Adeberg, S; Debus, J; Haefner, MF; Herfarth, K; Koerber, SA; Krug, D; Liermann, J; Seither, B; Slynko, A; Sterzing, F, 2019) |
"CRT for anal cancer is becoming a standard therapy but local recurrence is possible." | 1.51 | [A Case of Colostomy-Free and Long-Term Survival with 5-FU/CDDP for Local Recurrence of Anal Cancer after Chemoradiation Therapy]. ( Aoyama, Y; Hikosaka, Y; Karamatsu, S; Katada, T; Kato, A; Mita, K; Nishida, T; Nishido, T; Saito, M; Sakamoto, S; Shibata, T; Teranishi, F; Tsuchiya, T, 2019) |
" Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading." | 1.48 | Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018) |
"A retrospective cohort of 190 anal cancer patients treated at 3 academic centers with concurrent chemo-RT employing either SIB or SeqB was analysed." | 1.48 | Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study. ( Arcadipane, F; Casadei Gardini, A; Cassoni, P; Ceccarelli, M; Créhange, G; De Bari, B; Evangelista, A; Franco, P; Furfaro, G; Iorio, GC; Lepinoy, A; Martini, S; Mistrangelo, M; Passardi, A; Ricardi, U; Trino, E; Valgiusti, M, 2018) |
"Anal canal cancer occasionally accompanies extramammary Paget disease." | 1.48 | Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report. ( Hirose, S; Hyodo, I; Kawai, H; Moriwaki, T; Sato, M; Suganuma, D; Tajima, H; Uchida, Y; Watanabe, R; Yamada, T; Yamamoto, Y; Yamaura, M, 2018) |
"Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
"Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates." | 1.46 | Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017) |
"We report a case of perianal squamous cell carcinoma and left inguinal lymph node metastasis that showed a complete response more than 5 years after chemotherapy and concomitant proton beam therapy." | 1.46 | [A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy]. ( Abe, T; Azami, A; Honda, M; Nakamura, T; Sato, A; Suzuki, N; Tada, T; Takano, Y; Teranishi, Y; Todate, Y; Waragai, M, 2017) |
"Locally advanced anal cancer patients, especially with T4 disease and fistula, have a dismal prognosis." | 1.46 | Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer. ( Allal, AS; Cacheux, W; Dietrich, PY; Fernandez, E; Ho, L; Koessler, T; Puppa, G; Ris, F; Roche, B; Roth, A; Zilli, T, 2017) |
"Treatment with uridine triacetate was arranged in the emergency department." | 1.46 | The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. ( Geller, RJ; Morgan, BW; Santos, C, 2017) |
"However, anal cancers are rare in patients with HIV in Japan." | 1.43 | [Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV]. ( Ishida, H; Mita, E; Mori, K; Nakazuru, S; Nishio, K; Sakakibara, Y; Sugimoto, A; Uehira, T; Yajima, K; Yamada, T, 2016) |
"45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included." | 1.43 | Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. ( Behrendt, FF; Eble, MJ; Heinzel, A; Mohammadkhani Shali, S; Mottaghy, FM; Schmitt, V; Verburg, FA; Winz, OH, 2016) |
"Anal cancer was diagnosed in a 36-year-old nulliparous woman." | 1.43 | Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level. ( Biel, P; Cordes, T; Köhler, C; Marnitz, S, 2016) |
"Anal cancer is uncommon." | 1.42 | Review of anal cancer patients at the Ottawa hospital. ( Abunassar, M; Asmis, T; Jonker, DJ; Reinders, J, 2015) |
"TomoTherapy for locally advanced anal cancer is feasible." | 1.42 | French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients. ( Belhomme, S; Benech, J; Doussau, A; Frison, E; Henriques de Figueiredo, B; Kantor, G; Lisbona, A; Mahé, MA; Maire, JP; Nomikossoff, N; Rio, E; Vendrely, V, 2015) |
"Inguinal lymph node metastasis is predictive of locoregional recurrence and poor overall survival in anal carcinoma." | 1.40 | Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. ( Blinde, SE; Mens, JW; Nuyttens, JJ; Olofsen, M; Schasfoort, R; Verhoef, C, 2014) |
"Capecitabine is an established treatment alternative to intravenous 5-fluorouracil (5-FU) for patients with rectal cancer receiving chemoradiotherapy." | 1.40 | Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. ( Beijnen, JH; Cats, A; Dewit, L; Meulendijks, D; Schellens, JH; Tomasoa, NB; van Tinteren, H, 2014) |
"Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists." | 1.40 | The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. ( Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN, 2014) |
"The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life." | 1.39 | Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013) |
"Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity." | 1.38 | Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. ( Blaszkowsky, LS; Coen, JJ; Hartshorn, K; Hong, TS; Kachnic, LA; Kwak, EL; Ryan, DP; Tsai, HK; Willins, JD, 2012) |
"Sixty patients with anal cancer were identified." | 1.38 | Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. ( Alfa-Wali, M; Allen-Mersh, T; Antoniou, A; Bower, M; Gazzard, B; Nelson, M; Newsom-Davis, T; Tait, D, 2012) |
"CRT is a highly effective approach in anal cancer." | 1.38 | Twenty-five-year experience with radical chemoradiation for anal cancer. ( Chander, S; Chu, J; Foo, M; Heriot, A; Lee, MT; Leong, T; Link, E; Lynch, CA; Mackay, J; Michael, M; Ngan, SY; Tomaszewski, JM; Tran, P; Vazquez, M, 2012) |
"Pre- and post-treatment staging of anal cancer are often inaccurate." | 1.38 | Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012) |
"To update our experience in treating squamous cell carcinoma of the anal margin with definitive radiotherapy (RT)." | 1.37 | Squamous cell carcinoma of the anal margin: the university of Florida experience. ( Balamucki, CJ; George, TJ; Kirwan, JM; Mendenhall, WM; Morris, CG; Newlin, HE; Rout, WR; Zlotecki, RA, 2011) |
"HIV-positive patients with anal cancer can be treated with standard CRT, with the same tolerability and toxicity as HIV-negative patients." | 1.37 | Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? ( Fraunholz, I; Gerstein, J; Haberl, A; Jäck, K; Rabeneck, D; Rödel, C; Weiss, C, 2011) |
"A total of 88 patients treated for anal cancer at our institution between 1990 and 2006 were identified from our database." | 1.37 | Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. ( Hägele, V; Mai, SK; Welzel, G; Wenz, F, 2011) |
"Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 1.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
"Eighty-four patients with invasive anal cancer treated with definitive external beam radiotherapy (RT) with a mandatory split of 12 days (52 patients, Montreal, Canada) or without an intended split (32 patients, Zurich, Switzerland) were reviewed." | 1.36 | Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. ( Bahary, JP; Ciernik, IF; Donath, D; Lütolf, UM; Oehler, C; Provencher, S, 2010) |
"From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT." | 1.36 | Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( Donath, D; Fortin, B; Jolicoeur, M; Lavertu, S; Oehler, C; Provencher, S, 2010) |
"HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries." | 1.36 | Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. ( Ennis, RD; Evans, A; Grossbard, M; Hauerstock, D, 2010) |
"Blood test showed severe disseminated intravascular coagulation (DIC)." | 1.36 | [mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report]. ( Doi, M; Okamoto, Y; Shinozaki, K; Yamauchi, M, 2010) |
"We report three cases of anal canal squamous cell carcinoma treated with radiotherapy combined with S-1 and mitomycin C(MMC)." | 1.36 | [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas]. ( Akaike, M; Motohashi, O; Nakayama, N; Nakayama, Y; Nishimura, K; Nonaka, T; Shiozawa, M; Takagi, S; Yoshii, T, 2010) |
"We report a case of squamous cell carcinoma of the anus with associated HIV infection." | 1.36 | [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. ( Fujitani, K; Hirao, M; Ikenaga, M; Mishima, H; Miyamoto, A; Miyazaki, M; Nakamori, S; Omiya, H; Sueda, K; Takami, K; Tsujie, M; Tsujinaka, T; Yasui, M; Yoshida, K, 2010) |
"We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
"Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m(2), continuous infusion for 5 days q4 weeks." | 1.33 | Intermediate dose 5-fluorouracil-induced encephalopathy. ( Choi, HJ; Chung, HC; Jeung, HC; Kim, YA; Rha, SY; Seong, JS, 2006) |
"Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation." | 1.33 | The bottom line: outcomes after conservation treatment in anal cancer. ( Dwyer, MK; Gebski, VJ; Jayamohan, J, 2006) |
"We present a male patient with a perianal fistula of 30 years' duration that had been treated on several occasions." | 1.33 | [Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant chemoradiotherapy and laparoscopy-assisted abdominoperineal amputation]. ( Almendral, ML; Aranda, F; Echenique-Elizondo, M; Erro, JM; Ibáñez, J; Valenti, C, 2006) |
"Anal cancer is the first tumour in which chemoradiotherapy with the intent of organ preservation has largely replaced surgery and is an interesting model of modern multimodal oncological treatment." | 1.33 | Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. ( Arponen, P; Blomqvist, C; Saarilahti, K; Tenhunen, M; Vaalavirta, L, 2006) |
"Nine (18%) have died of anal cancer." | 1.32 | Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. ( Melcher, AA; Sebag-Montefiore, D, 2003) |
"Treatment of T3 and T4 anal cancer with combined chemotherapy and EBRT, followed by interstitial implant results in an ultimate local-regional control of 84%, after the inclusion of selected APR." | 1.32 | Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience. ( Cosmatos, HA; Hsiang, JY; Hwang, JM; Kagan, RA; Kaptein, JS; Rao, AR; Tome, M; Wang, R, 2004) |
"A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities." | 1.31 | Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy. ( Arnott, SJ; Leslie, MD; Subramaniam, R, 2002) |
"The median CD4 count at diagnosis of anal cancer was 209 cells/microl (range: 29-380 cells/microl), 5 had prior AIDS defining diagnoses." | 1.31 | Treatment of HIV-associated invasive anal cancer with combined chemoradiation. ( Bower, M; Cleator, S; Fife, K; Gazzard, B; Nelson, M; Phillips, R, 2000) |
"The effect of the treatment of anal cancer by performing a high-dose-rate (HDR) brachytherapy boost during a short split between the external beam radiotherapy series (EBR) +/- chemotherapy was investigated." | 1.31 | Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal. ( Berger, A; Gebhart, FH; Geyer, E; Hebenstreit, J; Kapp, KS; Oechs, AC; Stoeger, H, 2001) |
"We recently treated 2 patients with squamous cell carcinoma in the anal canal with bilateral inguinal nodal metastases using chemoradiotherapy." | 1.31 | [Two cases of squamous cell carcinoma of the anal canal treated with chemoradiotherapy]. ( Furutani, K; Fuwa, N; Kamata, M; Kodaira, T; Matsumoto, A; Sasaoka, M, 2001) |
"Retrospective review of 50 MO anal cancer patients treated from 1984-1994." | 1.30 | Time-dose considerations in the treatment of anal cancer. ( Constantinou, EC; Daly, W; DeLaney, TF; Fung, CY; Kaufman, DS; Willett, CG, 1997) |
"The standard treatment for anal cancer is combination chemo-radiotherapy." | 1.29 | The influence of age on the management of anal cancer. ( Basrur, V; de Gara, CJ; Figueredo, A; Goodyear, M; Knight, P, 1995) |
"Four hundred five patients with anal cancer were identified by computer search, and 204 (51%) were evaluable; 164 of 204 (80%) had squamous cell carcinoma, 137 of whom (84%) were treated with sphincter-preserving procedures, and 27 of whom (16%) were treated by by radical surgery." | 1.29 | Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. ( Coplin, MA; Johnson, FE; Longo, WE; Vernava, AM; Virgo, KS; Wade, TP, 1994) |
"Among them, three patients had acquired immunodeficiency syndrome (AIDS)." | 1.29 | Squamous-cell carcinoma of the anus in HIV-positive patients. ( Berson, A; Chadha, M; Malamud, S; Pisch, J; Rosenblatt, EA, 1994) |
"Seven patients had HIV, four of whom had acquired immunodeficiency syndrome." | 1.29 | Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. ( Holland, JM; Swift, PS, 1994) |
"The conventional surgical treatment of anal squamous cell carcinoma is abdominoperineal resection." | 1.29 | An alternative treatment of anal squamous cell carcinoma: combined radiotherapy and chemotherapy. ( Changchien, CR; Chen, JS; Fan, HA; Hsu, KC; Tang, R; Wang, JY; You, YT, 1993) |
"Results of 21 cases of squamous cell carcinoma of anal canal treated by continuous infusion of 5-fluorouracil 1000 mg/sqm for 4 days and mitomycin-C 15 mg/sqm on 1st day by i." | 1.29 | Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy. ( Mishra, RC; Sai, PL; Senapati, S, 1996) |
" Radiotherapy is often combined with concurrent chemotherapy although no firm evidence exists that such combinations are more effective than radiotherapy alone." | 1.28 | Induction chemotherapy with carboplatin and 5-fluorouracil in combination with radiotherapy in loco-regionally advanced epidermoid carcinoma of the anus--preliminary results. ( Goldman, S; Kaigas, M; Svensson, C, 1992) |
"Between 1979 and 1988, 33 patients with squamous cell carcinoma of the anal canal were treated with chemoradiation." | 1.28 | Squamous cell carcinoma of the anal canal. ( Fleshman, JW; Fry, RD; Halverson, JD; Kodner, IJ; Lopez, MJ; Monafo, WW; Myerson, RJ; Shapiro, SJ, 1991) |
"A 62-year-old female with anal cancer underwent Miles operation in November, 1987." | 1.28 | [Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer]. ( Amino, K; Mieno, K; Miura, S; Satoi, Y; Shikata, J; Takeda, Y, 1989) |
"We report preliminary results on treatment of anal carcinoma by radiotherapy and chemotherapy." | 1.28 | [Anal neoplasms. Treatment with radiotherapy and exclusive chemotherapy]. ( Armando, S; Arraztoa, J; Morales, Y; San Martín, S, 1989) |
"Seventy patients with squamous cell carcinoma or cloacogenic carcinoma of the anus treated from 1979-1987 were reviewed." | 1.28 | Radiotherapy for anal cancer: experience from 1979-1987. ( Ajani, JA; Delclos, L; Hughes, LL; Martin, RG; Rich, TA, 1989) |
"Twenty-eight patients with squamous cell carcinoma of the anal canal were treated by preoperative radiation therapy and chemotherapy." | 1.27 | Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. ( Considine, B; Kinzie, JJ; Leichman, L; Nigro, ND; Seydel, HG; Vaitkevicius, VK, 1983) |
" During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed." | 1.27 | [Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy]. ( Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987) |
"For many years surgery has been the treatment of choice for squamous cell carcinoma of the anus, but it is now becoming apparent that well-planned definitive radiation therapy combined with chemotherapy may obviate the need for an abdomino-perineal resection." | 1.27 | The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. ( Sischy, B, 1985) |
"Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months." | 1.26 | Response of metastatic cloacogenic carcinoma to treatment with semustine. ( Wampler, GL; Zimm, S, 1981) |
"In a 74-year-old man extramammary Paget's disease of the scrotal and perianal areas masqueraded as tinea cruris and chronic dermatitis for 7 years before it was diagnosed." | 1.26 | Extramammary Paget's disease. ( Goodall, J; Haberman, HF; Llewellyn, M, 1978) |
"A fourth patient with previously treated epidermoid carcinoma of the anus presented with biopsy-proven pulmonary metastasis and was placed on the chemotherapeutic regimen alone." | 1.26 | Multi-modality therapy for epidermoid carcinoma of the anus. ( Newman, HK; Quan, SH, 1976) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 52 (12.24) | 18.7374 |
1990's | 81 (19.06) | 18.2507 |
2000's | 86 (20.24) | 29.6817 |
2010's | 169 (39.76) | 24.3611 |
2020's | 37 (8.71) | 2.80 |
Authors | Studies |
---|---|
Nilsson, MP | 2 |
Gunnlaugsson, A | 2 |
Johnsson, A | 4 |
Scherman, J | 2 |
Guerra, GR | 1 |
Kong, JC | 1 |
Millen, RM | 1 |
Read, M | 1 |
Liu, DS | 1 |
Roth, S | 1 |
Sampurno, S | 1 |
Sia, J | 1 |
Bernardi, MP | 1 |
Chittleborough, TJ | 1 |
Behrenbruch, CC | 1 |
Teh, J | 1 |
Xu, H | 1 |
Haynes, NM | 1 |
Yu, J | 1 |
Lupat, R | 1 |
Hawkes, D | 1 |
Di Costanzo, N | 1 |
Tothill, RW | 1 |
Mitchell, C | 1 |
Ngan, SY | 3 |
Heriot, AG | 1 |
Ramsay, RG | 1 |
Phillips, WA | 1 |
Tchelebi, LT | 1 |
Eng, C | 5 |
Messick, CA | 2 |
Hong, TS | 4 |
Ludmir, EB | 3 |
Kachnic, LA | 10 |
Zaorsky, NG | 1 |
Stouvenot, M | 1 |
Meurisse, A | 2 |
Saint, A | 3 |
Buecher, B | 4 |
André, T | 3 |
Samalin, E | 4 |
Jary, M | 4 |
El Hajbi, F | 3 |
Baba-Hamed, N | 4 |
Pernot, S | 2 |
Kaminsky, MC | 1 |
Bouché, O | 3 |
Desrame, J | 3 |
Zoubir, M | 2 |
Smith, D | 3 |
Ghiringhelli, F | 2 |
Parzy, A | 3 |
de la Fouchardiere, C | 3 |
Almotlak, H | 1 |
Vienot, A | 2 |
Jacquin, M | 3 |
Taieb, J | 2 |
Nguyen, T | 3 |
Vernerey, D | 4 |
Borg, C | 7 |
Kim, S | 8 |
Johansson, M | 1 |
Axelsson, A | 1 |
Haglind, E | 1 |
Bock, D | 1 |
Angenete, E | 1 |
Radka, L | 1 |
Zdeňka, P | 1 |
Holliday, EB | 2 |
Morris, VK | 1 |
Johnson, B | 1 |
Das, P | 6 |
Minsky, BD | 4 |
Taniguchi, C | 1 |
Smith, GL | 1 |
Koay, EJ | 2 |
Koong, AC | 4 |
Delclos, ME | 1 |
Skibber, JM | 3 |
Rodriguez-Bigas, MA | 2 |
You, YN | 2 |
Bednarski, BK | 1 |
Tillman, MM | 1 |
Chang, GJ | 3 |
Jennings, K | 1 |
Citrin, D | 1 |
Valle, L | 1 |
Camphausen, K | 1 |
Cooley-Zgela, T | 1 |
Smart, D | 1 |
Yao, M | 1 |
Mitchell, JB | 1 |
Thompson, W | 1 |
Sereti, I | 1 |
Uldrick, T | 1 |
Neelis, KJ | 1 |
Kip, DM | 1 |
Speetjens, FM | 1 |
van der Linden, YM | 1 |
Lohynská, R | 2 |
Pechačová, Z | 1 |
Delhiat, AC | 1 |
Combet-Curt, V | 1 |
Vendrely, V | 6 |
Valery, M | 1 |
Cervantes, B | 1 |
Smolenschi, C | 1 |
Boilève, A | 1 |
Boige, V | 1 |
Malka, D | 2 |
Hollebecque, A | 1 |
Ducreux, M | 4 |
Patel, C | 1 |
Elmasry, A | 1 |
Giridharan, S | 1 |
Murofushi, KN | 1 |
Itasaka, S | 1 |
Shimokawa, M | 1 |
Murakami, Y | 1 |
Yamamoto, T | 1 |
Nishimura, Y | 1 |
Kudo, S | 1 |
Sakamoto, T | 1 |
Ariga, T | 1 |
Ogo, E | 1 |
Taguchi, K | 1 |
Jingu, K | 1 |
Ogawa, K | 1 |
Kharofa, JR | 4 |
Yothers, G | 3 |
Ajani, J | 5 |
Meyer, JE | 3 |
Augspurger, ME | 3 |
Okawara, GS | 4 |
Garg, MK | 4 |
Schefter, TE | 5 |
Swanson, TA | 3 |
Doncals, DE | 4 |
Kim, H | 3 |
Zaki, BI | 3 |
Narayan, S | 4 |
Lee, RJ | 3 |
Mamon, HJ | 3 |
Schwartz, MA | 3 |
Moughan, J | 9 |
Crane, CH | 10 |
Lukovic, J | 3 |
Hosni, A | 3 |
Liu, A | 3 |
Chen, J | 3 |
Tadic, T | 3 |
Patel, T | 3 |
Li, K | 3 |
Han, K | 3 |
Lindsay, P | 3 |
Craig, T | 3 |
Brierley, J | 3 |
Barry, A | 3 |
Wong, R | 3 |
Ringash, J | 3 |
Dawson, LA | 3 |
Kim, JJ | 3 |
Kumar, V | 2 |
Bansal, S | 2 |
Badola, A | 2 |
Nautiyal, V | 2 |
Gupta, M | 2 |
Ahmad, M | 2 |
Saini, S | 2 |
Matsuki, G | 1 |
Nakajima, T | 1 |
Ichise, N | 1 |
Nomura, K | 1 |
Fujikawa, M | 1 |
Kasai, M | 1 |
Okamoto, R | 1 |
Ikuta, S | 1 |
Nakamoto, Y | 1 |
Aihara, T | 1 |
Kajimoto, N | 1 |
Kakuno, A | 1 |
Yanagi, H | 1 |
Yamanaka, N | 1 |
Lemanski, C | 5 |
Pommier, P | 2 |
LE Malicot, K | 1 |
Rivin Del Campo, E | 2 |
Regnault, P | 1 |
Ronchin, P | 1 |
Crehange, G | 4 |
Tougeron, D | 2 |
Menager-Tabourel, E | 1 |
Diaz, O | 1 |
Hummelsberger, M | 1 |
Minsat, M | 2 |
Drouet, F | 1 |
Larrouy, A | 1 |
Peiffert, D | 11 |
Lievre, A | 1 |
Zasadny, X | 1 |
Hautefeuille, V | 1 |
Mornex, F | 3 |
Lepage, C | 1 |
Quero, L | 1 |
Schlosser, S | 1 |
Zalmanov, S | 1 |
Pfeffer, RM | 1 |
Lipski, Y | 1 |
Grinberg, V | 1 |
Kalmus, Y | 1 |
Levin, D | 1 |
Hod, K | 1 |
Ben David, MA | 1 |
Gul, SK | 1 |
Tepetam, H | 1 |
Yildiz, F | 2 |
Er, I | 1 |
Oksuz, DC | 1 |
Parvizi, M | 1 |
Ozden, AS | 1 |
Alicikus, ZA | 1 |
Sari, SY | 1 |
Alomari, O | 1 |
Gorken, IB | 1 |
Mineur, L | 2 |
Vazquez, L | 1 |
Belkacemi, M | 1 |
Toullec, C | 1 |
Bentaleb, N | 1 |
Boustany, R | 1 |
Plat, F | 1 |
Evesque, L | 2 |
Falk, AT | 2 |
Cavaglione, G | 3 |
Montagne, L | 1 |
Benezery, K | 4 |
Francois, E | 10 |
Agarwal, MS | 1 |
Hitchcock, KE | 1 |
Morris, CG | 3 |
George, TJ | 2 |
Mendenhall, WM | 4 |
Zlotecki, RA | 4 |
Matzinger, O | 3 |
Haustermans, K | 2 |
Glynne-Jones, R | 13 |
Winter, KA | 5 |
Konski, AA | 1 |
Ajani, JA | 13 |
Bosset, JF | 6 |
Hannoun-Levi, JM | 6 |
Puyraveau, M | 3 |
Chakravarthy, AB | 2 |
Meadows, H | 3 |
Northover, J | 2 |
Collette, L | 2 |
Christiaens, M | 1 |
Maingon, P | 4 |
Moreau, E | 1 |
Schmutz, JL | 1 |
Granel-Brocard, F | 1 |
Bursztejn, AC | 1 |
de Meric de Bellefon, M | 1 |
Castan, F | 1 |
Mazard, T | 1 |
Lenglet, A | 1 |
Demontoy, S | 1 |
Riou, O | 1 |
Llacer-Moscardo, C | 1 |
Fenoglietto, P | 2 |
Aillères, N | 1 |
Thezenas, S | 1 |
Debrigode, C | 1 |
Vieillot, S | 2 |
Gourgou, S | 1 |
Azria, D | 2 |
Sauter, M | 1 |
Lombriser, N | 1 |
Bütikofer, S | 1 |
Keilholz, G | 1 |
Kranzbühler, H | 1 |
Heinrich, H | 1 |
Rogler, G | 1 |
Vavricka, SR | 1 |
Misselwitz, B | 1 |
Raphael, MJ | 1 |
Ko, G | 1 |
Booth, CM | 1 |
Brogly, SB | 1 |
Li, W | 1 |
Kalyvas, M | 1 |
Hanna, TP | 1 |
Patel, SV | 1 |
Bidard, FC | 3 |
Dahan, L | 1 |
Rebucci-Peixoto, M | 1 |
Spehner, L | 3 |
Kouzy, R | 1 |
Abi Jaoude, J | 1 |
Lin, D | 1 |
El Alam, MB | 1 |
Klopp, AH | 1 |
Colbert, LE | 1 |
Taniguchi, CM | 1 |
Leiker, AJ | 1 |
Wang, CJ | 1 |
Sanford, NN | 1 |
Aguilera, TA | 1 |
Karri, S | 1 |
Beg, MS | 1 |
Kazmi, SA | 1 |
Olson, C | 1 |
Matthews, JA | 1 |
Abdelnaby, A | 1 |
Meyer, JJ | 2 |
Folkert, MR | 1 |
Nýdlová, A | 1 |
Drbohlavová, T | 1 |
Mazaná, E | 1 |
Jirkovská, M | 1 |
Veselský, T | 1 |
Malinová, B | 1 |
Stankušová, H | 1 |
Adotevi, O | 1 |
Abdeljaoued, S | 1 |
Rao, S | 2 |
Singh, K | 1 |
Sathyamurthy, A | 1 |
Ramireddy, JK | 1 |
Ram, TS | 1 |
Cabel, L | 1 |
Lightner, AL | 1 |
Vaidya, P | 1 |
McMichael, J | 1 |
Click, B | 1 |
Regueiro, M | 1 |
Steele, SR | 1 |
Hull, TL | 1 |
Astaras, C | 1 |
Bornand, A | 1 |
Koessler, T | 3 |
Olsen, JR | 2 |
Myerson, R | 4 |
Abitbol, A | 1 |
Johnson, D | 2 |
Chen, Y | 1 |
Fisher, B | 1 |
Michalski, J | 1 |
Chang, A | 2 |
Kachnic, L | 2 |
Zimmermann, M | 1 |
Beer, J | 1 |
Bodis, S | 1 |
von Moos, R | 1 |
Vlachopoulou, V | 1 |
Zwahlen, DR | 1 |
Oehler, C | 3 |
Coen, M | 1 |
Rigamonti, F | 1 |
Roth, A | 4 |
Follana, P | 3 |
Tuan Falk, A | 1 |
Doyen, J | 3 |
Reure, J | 1 |
Suzuki, N | 1 |
Azami, A | 1 |
Todate, Y | 1 |
Tada, T | 1 |
Waragai, M | 1 |
Honda, M | 1 |
Sato, A | 1 |
Takano, Y | 1 |
Abe, T | 1 |
Nakamura, T | 1 |
Teranishi, Y | 1 |
Dumont, S | 1 |
Louvet, C | 1 |
Bachet, JB | 1 |
Abdelghani, MB | 1 |
Aparicio, T | 1 |
Bennouna, J | 1 |
Gornet, JM | 2 |
Bonnetain, F | 2 |
Smith, CA | 1 |
Cacheux, W | 1 |
Puppa, G | 1 |
Fernandez, E | 1 |
Ho, L | 1 |
Dietrich, PY | 1 |
Zilli, T | 3 |
Allal, AS | 8 |
Roche, B | 2 |
Ris, F | 2 |
Savale, L | 1 |
Chaumais, MC | 1 |
Dorfmuller, P | 1 |
Humbert, M | 1 |
Montani, D | 1 |
Franco, P | 6 |
Montagnani, F | 1 |
Arcadipane, F | 6 |
Casadei, C | 1 |
Andrikou, K | 1 |
Martini, S | 2 |
Iorio, GC | 2 |
Scartozzi, M | 1 |
Mistrangelo, M | 7 |
Fornaro, L | 1 |
Cassoni, P | 7 |
Cascinu, S | 1 |
Ricardi, U | 7 |
Casadei Gardini, A | 3 |
Safran, H | 2 |
Leonard, KL | 1 |
Perez, K | 1 |
Vrees, M | 1 |
Klipfel, A | 1 |
Schechter, S | 1 |
Oldenburg, N | 1 |
Roth, L | 1 |
Shah, N | 1 |
Rosati, K | 1 |
Rajdev, L | 2 |
Mantripragada, K | 1 |
Sheng, IY | 1 |
Barth, P | 1 |
DiPetrillo, TA | 1 |
Jones, CM | 1 |
Adams, R | 3 |
Downing, A | 2 |
Harrison, M | 2 |
Hawkins, M | 1 |
Sebag-Montefiore, D | 12 |
Gilbert, DC | 1 |
Muirhead, R | 1 |
Sclafani, F | 1 |
Pittman, ME | 1 |
Milsom, J | 1 |
Yantiss, RK | 1 |
Ng, M | 1 |
Ho, H | 1 |
Skelton, J | 1 |
Guerrieri, M | 1 |
Guiney, M | 1 |
Chao, M | 1 |
Blakey, D | 1 |
Macleod, C | 1 |
Amor, H | 1 |
Subramanian, B | 1 |
Melven, L | 1 |
Faivre, JC | 1 |
Mirabel, X | 4 |
Stanbury, T | 1 |
Salleron, J | 1 |
Guillemin, F | 1 |
De Bari, B | 4 |
Lepinoy, A | 2 |
Ceccarelli, M | 1 |
Furfaro, G | 1 |
Valgiusti, M | 1 |
Passardi, A | 2 |
Trino, E | 1 |
Evangelista, A | 1 |
Esin, E | 1 |
Laçin, Ş | 1 |
Karakaş, Y | 1 |
Gültekin, M | 1 |
Dizdar, Ö | 1 |
Yalçın, Ş | 1 |
Mondaca, S | 1 |
Chatila, WK | 1 |
Bates, D | 1 |
Hechtman, JF | 1 |
Cercek, A | 1 |
Segal, NH | 1 |
Stadler, ZK | 1 |
Varghese, AM | 1 |
Kundra, R | 1 |
Capanu, M | 1 |
Shia, J | 1 |
Schultz, N | 1 |
Saltz, L | 1 |
Yaeger, R | 1 |
Elson, JK | 1 |
Ott, OJ | 1 |
Schmidt, M | 1 |
Semrau, S | 1 |
Strnad, V | 1 |
Matzel, KE | 2 |
Schneider, I | 1 |
Raptis, D | 1 |
Uter, W | 1 |
Grützmann, R | 1 |
Fietkau, R | 1 |
Yamaura, M | 1 |
Yamada, T | 2 |
Watanabe, R | 1 |
Kawai, H | 1 |
Hirose, S | 1 |
Tajima, H | 1 |
Sato, M | 1 |
Uchida, Y | 1 |
Suganuma, D | 1 |
Yamamoto, Y | 2 |
Moriwaki, T | 1 |
Hyodo, I | 1 |
Koerber, SA | 1 |
Seither, B | 1 |
Slynko, A | 1 |
Haefner, MF | 1 |
Krug, D | 1 |
Liermann, J | 1 |
Adeberg, S | 1 |
Herfarth, K | 1 |
Debus, J | 1 |
Sterzing, F | 1 |
Sato, H | 2 |
Koide, Y | 2 |
Shiota, M | 2 |
Mizuno, M | 1 |
Morise, Z | 1 |
Uyama, I | 1 |
Ladbury, C | 1 |
A Goodman, K | 1 |
Aoyama, Y | 1 |
Katada, T | 1 |
Saito, M | 1 |
Tsuchiya, T | 1 |
Nishido, T | 1 |
Kato, A | 1 |
Shibata, T | 2 |
Teranishi, F | 1 |
Sakamoto, S | 1 |
Mita, K | 1 |
Karamatsu, S | 1 |
Hikosaka, Y | 1 |
Nishida, T | 1 |
Martin, D | 2 |
Rödel, C | 9 |
Fokas, E | 3 |
Wo, JY | 2 |
Plastaras, JP | 1 |
Metz, JM | 1 |
Jiang, W | 1 |
Yeap, BY | 1 |
Drapek, LC | 2 |
Adams, J | 1 |
Baglini, C | 1 |
Ryan, DP | 2 |
Murphy, JE | 2 |
Parikh, AR | 1 |
Allen, JN | 2 |
Clark, JW | 1 |
Blaszkowsky, LS | 3 |
DeLaney, TF | 2 |
Ben-Josef, E | 2 |
Giuliani, A | 1 |
Romanzi, F | 1 |
Di Sibio, A | 1 |
Calvisi, G | 1 |
Lombardi, L | 1 |
Marchese, M | 1 |
Di Staso, M | 1 |
Schietroma, M | 1 |
Carlei, F | 1 |
Romano, L | 1 |
Wieland, U | 4 |
Kreuter, A | 2 |
Richel, O | 2 |
de Vries, HJ | 2 |
van Noesel, CJ | 1 |
Dijkgraaf, MG | 1 |
Prins, JM | 2 |
Deenen, MJ | 1 |
Dewit, L | 3 |
Boot, H | 1 |
Beijnen, JH | 2 |
Schellens, JH | 2 |
Cats, A | 3 |
James, RD | 1 |
Meadows, HM | 4 |
Cunningham, D | 2 |
Myint, AS | 1 |
Saunders, MP | 1 |
Maughan, T | 1 |
McDonald, A | 2 |
Essapen, S | 1 |
Leslie, M | 3 |
Falk, S | 3 |
Wilson, C | 1 |
Gollins, S | 4 |
Begum, R | 1 |
Ledermann, J | 2 |
Kadalayil, L | 1 |
Herman, JM | 1 |
Thomas, CR | 7 |
Malet, C | 1 |
Gérard, JP | 10 |
Betz, M | 2 |
Bieri, S | 1 |
Roth, AD | 4 |
Nieder, C | 1 |
Olivatto, LO | 1 |
Vieira, FM | 1 |
Pereira, BV | 1 |
Victorino, AP | 1 |
Bezerra, M | 1 |
Araujo, CM | 1 |
Erlich, F | 1 |
Faroni, L | 1 |
Castro, L | 1 |
Lusis, EC | 1 |
Marins, A | 1 |
Ferreira, CG | 1 |
DeFoe, SG | 2 |
Kabolizadeh, P | 2 |
Heron, DE | 2 |
Beriwal, S | 2 |
Fraunholz, I | 6 |
Rödel, F | 4 |
Kohler, D | 2 |
Diallo-Georgiopoulou, M | 1 |
Distel, L | 2 |
Ortholan, C | 3 |
Gal, J | 1 |
Badakhshi, H | 1 |
Budach, V | 3 |
Wust, P | 2 |
Graf, R | 2 |
Deutsch, E | 1 |
Pignon, JP | 2 |
Levy, A | 1 |
Delarochefordiere, A | 1 |
Martel-Lafay, I | 1 |
Rio, E | 2 |
Conroy, T | 3 |
Miglianico, L | 1 |
Becouarn, Y | 1 |
Malekzadeh, K | 1 |
Paris, E | 1 |
Juzyna, B | 1 |
Ezra, P | 1 |
Gunderson, LL | 4 |
Pedersen, JE | 2 |
Benson, AB | 7 |
Mayer, RJ | 5 |
Haddock, MG | 5 |
Rich, TA | 6 |
Willett, CG | 7 |
Mansi, L | 1 |
Benzidane, B | 1 |
Cazorla, A | 1 |
Demarchi, M | 1 |
Kaliski, A | 1 |
Delabrousse, E | 1 |
Letondal, P | 1 |
Valmary-Degano, S | 1 |
Bazan, JG | 4 |
Luxton, G | 2 |
Kozak, MM | 1 |
Anderson, EM | 1 |
Hancock, SL | 1 |
Kapp, DS | 3 |
Kidd, EA | 1 |
Chang, DT | 4 |
Bejarano, PA | 1 |
Boutros, M | 1 |
Berho, M | 1 |
Oashi, K | 1 |
Tsutsumida, A | 1 |
Namikawa, K | 1 |
Tanaka, R | 1 |
Omata, W | 1 |
Yamazaki, N | 1 |
Call, JA | 1 |
Prendergast, BM | 1 |
Jensen, LG | 1 |
Ord, CB | 1 |
Goodman, KA | 5 |
Jacob, R | 1 |
Mell, LK | 6 |
Jabbour, SK | 1 |
Miller, RC | 4 |
Foo, M | 2 |
Link, E | 2 |
Leong, T | 2 |
Chu, J | 2 |
Lee, MT | 2 |
Chander, S | 2 |
Tran, PK | 1 |
Tomaszewski, JM | 2 |
Michael, M | 2 |
Heriot, A | 2 |
Claren, A | 1 |
Frin, AC | 1 |
Mari, V | 1 |
Fraunholz, IB | 2 |
Haberl, A | 3 |
Klauke, S | 1 |
Gute, P | 1 |
Rödel, CM | 1 |
Capelli, L | 1 |
Ulivi, P | 1 |
Giannini, M | 1 |
Freier, E | 1 |
Tamberi, S | 1 |
Scarpi, E | 1 |
Zoli, W | 1 |
Ragazzini, A | 1 |
Amadori, D | 1 |
Frassineti, GL | 1 |
Buglione, M | 1 |
Maddalo, M | 1 |
Lestrade, L | 2 |
Spiazzi, L | 1 |
Vitali, P | 1 |
Barbera, F | 1 |
Magrini, SM | 1 |
Blinde, SE | 1 |
Schasfoort, R | 1 |
Mens, JW | 1 |
Verhoef, C | 1 |
Olofsen, M | 1 |
Nuyttens, JJ | 1 |
Kitz, J | 2 |
Rave-Fränk, M | 3 |
Wolff, HA | 2 |
Weiss, C | 4 |
Wirtz, R | 1 |
Balermpas, P | 2 |
Thind, G | 1 |
Johal, B | 1 |
Follwell, M | 1 |
Kennecke, HF | 1 |
Siegel, EM | 1 |
Eschrich, S | 1 |
Winter, K | 2 |
Riggs, B | 1 |
Berglund, A | 1 |
Ajidahun, A | 1 |
Simko, J | 1 |
Magliocco, A | 1 |
Elahi, A | 1 |
Hoffe, S | 1 |
Shibata, D | 1 |
Carmona, R | 1 |
Pritz, J | 1 |
Bydder, M | 2 |
Gulaya, S | 1 |
Zhu, H | 1 |
Williamson, CW | 1 |
Welch, CS | 1 |
Vaida, F | 1 |
Bydder, G | 1 |
Meulendijks, D | 2 |
Tomasoa, NB | 2 |
van Tinteren, H | 1 |
Rodriguez-Bigas, M | 1 |
Xing, Y | 1 |
Vauthey, JN | 1 |
Rogers, JE | 1 |
Ohinata, A | 1 |
Pathak, P | 2 |
Sethi, S | 1 |
Phillips, JK | 1 |
Wolff, RA | 3 |
Leon, O | 2 |
Guren, M | 1 |
Hagberg, O | 1 |
Glimelius, B | 2 |
Dahl, O | 3 |
Havsteen, H | 1 |
Naucler, G | 1 |
Svensson, C | 3 |
Tveit, KM | 4 |
Jakobsen, A | 1 |
Pfeiffer, P | 1 |
Wanderås, E | 1 |
Ekman, T | 1 |
Lindh, B | 1 |
Balteskard, L | 3 |
Frykholm, G | 2 |
Ghosn, M | 1 |
Kourie, HR | 1 |
Abdayem, P | 1 |
Antoun, J | 1 |
Nasr, D | 1 |
Troussier, I | 2 |
Huguet, F | 2 |
Servagi-Vernat, S | 1 |
Benahim, C | 1 |
Khalifa, J | 1 |
Darmon, I | 1 |
Krebs, L | 1 |
Dejean, C | 1 |
Bensadoun, RJ | 1 |
Thariat, J | 1 |
Abunassar, M | 1 |
Reinders, J | 1 |
Jonker, DJ | 1 |
Asmis, T | 1 |
El-Hadaad, HA | 1 |
Wahba, HA | 1 |
Roshdy, S | 1 |
Yeung, R | 1 |
McConnell, Y | 1 |
Warkentin, H | 3 |
Graham, D | 1 |
Warkentin, B | 1 |
Joseph, K | 3 |
Doll, CM | 2 |
Munoz, F | 1 |
Sciacero, P | 1 |
Spadi, R | 1 |
Migliaccio, F | 1 |
Angelini, V | 1 |
Bombaci, S | 1 |
Rondi, N | 4 |
Numico, G | 1 |
Ragona, R | 4 |
Morino, M | 5 |
Racca, P | 5 |
Julie, DA | 1 |
Oh, JH | 1 |
Apte, AP | 1 |
Deasy, JO | 1 |
Tom, A | 1 |
Wu, AJ | 1 |
Borycka-Kiciak, K | 1 |
Białas, A | 1 |
Wejman, J | 1 |
Uchman-Musielak, M | 1 |
Tarnowski, W | 1 |
Morris, EJ | 1 |
Aravani, A | 1 |
Finan, PJ | 1 |
Lawton, S | 1 |
Thomas, JD | 1 |
Voong, KR | 1 |
Rashid, A | 2 |
Krishnan, S | 1 |
Yao, JC | 1 |
Feig, BW | 1 |
Henriques de Figueiredo, B | 1 |
Benech, J | 1 |
Belhomme, S | 1 |
Lisbona, A | 1 |
Frison, E | 1 |
Doussau, A | 1 |
Nomikossoff, N | 1 |
Mahé, MA | 2 |
Kantor, G | 1 |
Maire, JP | 1 |
Lescut, N | 1 |
Caubet, M | 1 |
Boustani, J | 1 |
Lakkis, Z | 1 |
Fantoli, M | 1 |
Buffet-Miny, J | 1 |
Bednarek, C | 1 |
Nijjar, Y | 1 |
Schiller, D | 2 |
Tankel, K | 2 |
Usmani, N | 2 |
Severin, D | 2 |
Ghosh, S | 2 |
Syme, A | 1 |
Nijjar, T | 2 |
Mulder, K | 2 |
Doll, C | 1 |
Wong, C | 2 |
Field, C | 2 |
White, EC | 1 |
Goldman, K | 1 |
Aleshin, A | 1 |
Lien, WW | 1 |
Rao, AR | 4 |
Yates, A | 1 |
Carroll, S | 1 |
Kneebone, A | 1 |
Tse, R | 1 |
Horvath, L | 1 |
Byrne, C | 1 |
Solomon, M | 1 |
Hruby, G | 1 |
Belgioia, L | 1 |
Vagge, S | 1 |
Agnese, D | 1 |
Garelli, S | 1 |
Murialdo, R | 1 |
Fornarini, G | 1 |
Chiara, S | 1 |
Gallo, F | 1 |
Bacigalupo, A | 1 |
Corvò, R | 2 |
Shi, L | 1 |
Li, X | 1 |
Pei, H | 1 |
Zhao, J | 1 |
Qiang, W | 1 |
Wang, J | 1 |
Xu, B | 1 |
Chen, L | 1 |
Wu, J | 1 |
Ji, M | 1 |
Lu, Q | 1 |
Li, Z | 1 |
Wang, H | 1 |
Jiang, J | 1 |
Wu, C | 1 |
Mai, S | 1 |
Welzel, G | 2 |
Ottstadt, M | 1 |
Lohr, F | 1 |
Severa, S | 1 |
Prigge, ES | 1 |
Wentzensen, N | 1 |
Trunk, MJ | 1 |
Wenz, F | 3 |
von Knebel-Doeberitz, M | 1 |
Reuschenbach, M | 1 |
Glebovskaya, VV | 1 |
Tkachev, SI | 1 |
Rasulov, AO | 1 |
Tsaryuk, VF | 1 |
Gordeev, SS | 1 |
Fedyanin, MY | 1 |
Aliev, VA | 1 |
Mamedly, ZZ | 1 |
Kuzmichev, DV | 1 |
Trofimova, OP | 1 |
Borisova, TN | 1 |
Yazhgunovich, IP | 1 |
Guren, MG | 2 |
Radu, C | 1 |
Oliveira, SC | 1 |
Moniz, CM | 1 |
Riechelmann, R | 1 |
Alex, AK | 1 |
Braghirolli, MI | 1 |
Bariani, G | 1 |
Nahas, C | 1 |
Hoff, PM | 1 |
Sugimoto, A | 1 |
Nakazuru, S | 1 |
Sakakibara, Y | 1 |
Nishio, K | 1 |
Ishida, H | 1 |
Yajima, K | 1 |
Uehira, T | 1 |
Mori, K | 1 |
Mita, E | 1 |
Nijkamp, J | 1 |
Julie, DR | 1 |
Rose, BS | 2 |
Jee, KW | 1 |
Niemierko, A | 1 |
Lee, LK | 1 |
Wang, Y | 1 |
Jumeau, R | 1 |
Bouchaab, H | 1 |
Vallet, V | 1 |
Mirimanoff, RO | 1 |
Wagner, AD | 1 |
Hanhloser, D | 1 |
Bourhis, J | 1 |
Ozsahin, EM | 1 |
Amraotkar, AR | 1 |
Pachika, A | 1 |
Grubb, KJ | 1 |
DeFilippis, AP | 1 |
Vos, LJ | 1 |
Paulson, K | 1 |
Polkosnik, LA | 1 |
Mohammadkhani Shali, S | 1 |
Schmitt, V | 1 |
Behrendt, FF | 1 |
Winz, OH | 1 |
Heinzel, A | 1 |
Mottaghy, FM | 1 |
Eble, MJ | 1 |
Verburg, FA | 1 |
Helmke, C | 1 |
Matthess, Y | 1 |
Raab, M | 1 |
Strebhardt, K | 1 |
Köhler, C | 1 |
Marnitz, S | 1 |
Biel, P | 1 |
Cordes, T | 1 |
Vaudo, CE | 1 |
Gil, B | 1 |
Galuski, K | 1 |
Zarwan, C | 1 |
Nugent, FW | 1 |
Santos, C | 1 |
Morgan, BW | 1 |
Geller, RJ | 1 |
Czito, BG | 3 |
Sparano, JA | 2 |
Lee, JY | 1 |
Palefsky, J | 2 |
Henry, DH | 1 |
Wachsman, W | 1 |
Aboulafia, D | 1 |
Ratner, L | 1 |
Fitzgerald, TJ | 2 |
Mitsuyasu, R | 1 |
Das, M | 1 |
Zhao, F | 1 |
Whittington, R | 1 |
Mitchell, EP | 1 |
Mulcahy, MF | 1 |
Armstrong, KI | 1 |
Nabbout, NH | 1 |
Kalnicki, S | 1 |
El-Rayes, BF | 1 |
Onitilo, AA | 1 |
Moriarty, DJ | 1 |
Lee, AY | 1 |
Golden, DW | 1 |
Kopec, M | 1 |
Pelizzari, CA | 1 |
Aggarwal, S | 1 |
Liauw, SL | 2 |
Klimowicz, A | 1 |
Ho, CK | 1 |
Kornaga, EN | 1 |
Lees-Miller, SP | 1 |
Berk, LB | 1 |
Roof, KS | 1 |
Becker, MJ | 1 |
Grisell, DL | 1 |
Ellis, RJ | 1 |
Sperduto, PW | 1 |
Marsa, GW | 1 |
Guha, C | 1 |
Magliocco, AM | 1 |
Kim, DW | 1 |
Byer, J | 1 |
Kothari, N | 1 |
Mahipal, A | 1 |
Chang, YD | 1 |
Kim, RD | 1 |
Chong, LC | 1 |
Healey, T | 1 |
Michele, T | 1 |
Price, TJ | 1 |
Mawdsley, S | 1 |
Pedersen, J | 2 |
Seo, Y | 1 |
Kinsella, MT | 1 |
Reynolds, HL | 1 |
Chipman, G | 1 |
Remick, SC | 1 |
Kinsella, TJ | 1 |
Oblak, I | 1 |
Petric, P | 1 |
Anderluh, F | 1 |
Velenik, V | 1 |
Hudej, R | 1 |
Fras, AP | 1 |
Myerson, RJ | 4 |
Outlaw, ED | 1 |
Birnbaum, EH | 1 |
Fleshman, JW | 2 |
Grigsby, PW | 1 |
Kodner, IJ | 2 |
Malayapa, RS | 1 |
Mutch, MG | 1 |
Parikh, P | 1 |
Picus, J | 1 |
Tan, BR | 1 |
Wang, X | 1 |
Izzo, JG | 1 |
Hogg, ME | 1 |
Popowich, DA | 1 |
Wang, EC | 1 |
Kiel, KD | 1 |
Stryker, SJ | 1 |
Halverson, AL | 1 |
Roelofsen, F | 3 |
Koswig, S | 1 |
Van Der Steen-Banasik, EM | 1 |
Van Houtte, P | 1 |
Radosevic-Jelic, L | 1 |
Mueller, RP | 1 |
Devisetty, K | 3 |
Salama, JK | 3 |
Schomas, DA | 3 |
Jani, AB | 4 |
Roeske, JC | 3 |
Aydogan, B | 2 |
Chmura, SJ | 4 |
Eberlein, K | 1 |
Armstrong, N | 1 |
Foley, G | 1 |
Wilson, J | 1 |
Finan, P | 1 |
Hill, J | 1 |
Pepek, JM | 1 |
Yoo, S | 1 |
Yoshitani, S | 1 |
Hosokawa, K | 1 |
Yokoi, M | 1 |
Kinami, S | 1 |
Omote, K | 1 |
Ueda, N | 1 |
Nakano, Y | 1 |
Kosaka, T | 1 |
Jiang, Y | 1 |
Mackley, H | 1 |
Cheng, H | 1 |
Fayaz, S | 1 |
Vasishta, S | 1 |
Motawy, M | 1 |
Wright, JL | 1 |
Patil, SM | 1 |
Temple, LK | 1 |
Saltz, LB | 1 |
James, R | 2 |
Wan, S | 2 |
Jitlal, M | 3 |
Rughani, AI | 1 |
Lin, C | 1 |
Tranmer, BI | 1 |
Wilson, JT | 1 |
Provencher, S | 2 |
Donath, D | 2 |
Bahary, JP | 1 |
Lütolf, UM | 2 |
Ciernik, IF | 2 |
Abbas, A | 2 |
Yang, G | 1 |
Fakih, M | 2 |
Lavertu, S | 1 |
Jolicoeur, M | 1 |
Fortin, B | 1 |
Rabeneck, D | 2 |
Raus, I | 1 |
Jung, K | 1 |
Schüler, P | 1 |
Herrmann, MK | 1 |
Hennies, S | 1 |
Vorwerk, H | 1 |
Hille, A | 1 |
Hess, CF | 1 |
Christiansen, H | 1 |
Brockmeyer, NH | 1 |
van Noesel, C | 1 |
Potthoff, A | 1 |
Balamucki, CJ | 1 |
Rout, WR | 1 |
Newlin, HE | 2 |
Kirwan, JM | 1 |
Hauerstock, D | 1 |
Ennis, RD | 1 |
Grossbard, M | 1 |
Evans, A | 1 |
Northover, JM | 2 |
Flam, M | 5 |
Gunderson, L | 1 |
Pollock, J | 1 |
Anne, R | 1 |
Rosenthal, SA | 1 |
Willett, C | 3 |
Yamauchi, M | 1 |
Okamoto, Y | 1 |
Doi, M | 1 |
Shinozaki, K | 1 |
Tsai, HK | 1 |
Coen, JJ | 1 |
Hartshorn, K | 1 |
Kwak, EL | 1 |
Willins, JD | 1 |
Shiozawa, M | 1 |
Nishimura, K | 1 |
Nonaka, T | 1 |
Yoshii, T | 1 |
Nakayama, N | 1 |
Motohashi, O | 1 |
Takagi, S | 1 |
Nakayama, Y | 1 |
Akaike, M | 1 |
Gerstein, J | 1 |
Jäck, K | 1 |
Maeda, K | 2 |
Matsuoka, H | 1 |
Noro, T | 1 |
Honda, K | 1 |
Endo, T | 1 |
Ozeki, S | 1 |
Fukuda, M | 1 |
Sueda, K | 1 |
Ikenaga, M | 2 |
Miyazaki, M | 1 |
Yasui, M | 1 |
Mishima, H | 2 |
Tsujie, M | 1 |
Omiya, H | 1 |
Miyamoto, A | 1 |
Hirao, M | 2 |
Takami, K | 1 |
Fujitani, K | 2 |
Nakamori, S | 1 |
Yoshida, K | 1 |
Tsujinaka, T | 2 |
Moureau-Zabotto, L | 2 |
Viret, F | 1 |
Giovaninni, M | 1 |
Lelong, B | 1 |
Bories, E | 1 |
Delpero, JR | 2 |
Pesenti, C | 1 |
Caillol, F | 1 |
de Chaisemartin, C | 1 |
Monges, G | 1 |
Sarran, A | 1 |
Resbeut, M | 1 |
Hara, W | 1 |
Hsu, A | 1 |
Kunz, PA | 1 |
Ford, J | 1 |
Fisher, GA | 2 |
Welton, ML | 2 |
Shelton, A | 1 |
Zampino, MG | 1 |
Magni, E | 1 |
Leonardi, MC | 1 |
Santoro, L | 1 |
Petazzi, E | 1 |
Fodor, C | 1 |
Petralia, G | 1 |
Trovato, C | 1 |
Nolè, F | 1 |
Orecchia, R | 1 |
Hägele, V | 1 |
Mai, SK | 2 |
Alfa-Wali, M | 1 |
Allen-Mersh, T | 1 |
Antoniou, A | 1 |
Tait, D | 2 |
Newsom-Davis, T | 1 |
Gazzard, B | 2 |
Nelson, M | 2 |
Bower, M | 2 |
Catalano, PJ | 1 |
Martenson, JA | 3 |
Mondschein, JK | 1 |
Wagner, H | 2 |
Mansour, EG | 2 |
Talamonti, MS | 2 |
Thang, NN | 1 |
Cochet, S | 1 |
George, AC | 1 |
Schick, U | 1 |
Ozsahin, M | 1 |
Gervaz, P | 2 |
Vazquez, M | 1 |
Lynch, CA | 1 |
Mackay, J | 1 |
Tran, P | 1 |
Ioannidis, O | 1 |
Papaemmanouil, S | 1 |
Paraskevas, G | 1 |
Chatzopoulos, S | 1 |
Kotronis, A | 1 |
Papadimitriou, N | 1 |
Makrantonakis, A | 1 |
Kakoutis, E | 1 |
Dalmases, M | 1 |
Lucena, CM | 1 |
Cano-Jiménez, E | 1 |
Xaubet, A | 1 |
Agustí, C | 1 |
Jones, H | 1 |
Rakfal, S | 1 |
Smith, RP | 1 |
Lalonde, R | 1 |
Chekrine, T | 1 |
Shakir Shakir, I | 1 |
Ardiet, JM | 3 |
Chapet, O | 1 |
Nehme, E | 1 |
Makino, S | 1 |
Ide, Y | 1 |
Murata, K | 1 |
Imada, S | 1 |
Ohue, M | 1 |
Noura, S | 1 |
Shingai, T | 1 |
Motoori, M | 1 |
Kishi, K | 1 |
Miyashiro, I | 1 |
Nishiyama, K | 1 |
Yano, M | 1 |
Ishikawa, O | 1 |
Myklebust, MP | 1 |
Fluge, Ø | 1 |
Immervoll, H | 1 |
Skarstein, A | 1 |
Bruland, O | 1 |
Yi, SK | 1 |
Mak, W | 1 |
Yang, CC | 1 |
Liu, T | 1 |
Cui, J | 1 |
Chen, AM | 1 |
Purdy, JA | 1 |
Monjazeb, AM | 1 |
Do, L | 1 |
Mok, EC | 1 |
Bentzen, AG | 1 |
Wanderås, EH | 1 |
Wilsgaard, T | 1 |
Pelosi, E | 1 |
Bellò, M | 1 |
Milanesi, E | 1 |
Baccega, M | 1 |
Filippini, C | 1 |
Lesca, A | 1 |
Munoz, FH | 1 |
Fora, G | 1 |
Skanjeti, A | 1 |
Cravero, F | 1 |
Robertson, B | 1 |
Shepherd, L | 1 |
Abratt, RP | 1 |
Hunter, A | 1 |
Goldberg, P | 1 |
Liang, Y | 1 |
Yashar, CM | 1 |
Cornell, M | 1 |
Hoh, CK | 1 |
Lawson, JD | 1 |
Einck, J | 1 |
Saenz, C | 1 |
Fanta, P | 1 |
Mundt, AJ | 3 |
Bydder, GM | 1 |
Satake, H | 1 |
Yoshino, T | 1 |
Sasaki, T | 1 |
Bando, H | 1 |
Yoda, Y | 1 |
Ikematsu, H | 1 |
Kojima, T | 1 |
Fuse, N | 1 |
Zenda, S | 1 |
Doi, T | 1 |
Kaneko, K | 1 |
Ohtsu, A | 1 |
Plowman, PN | 1 |
Hurman, DC | 1 |
Davidson, N | 1 |
Grieve, R | 1 |
Levine, E | 2 |
Margolin, DA | 1 |
Ambrosy, AP | 1 |
Kunz, PL | 1 |
Witteles, RM | 1 |
Hentic, O | 1 |
Hammel, P | 1 |
Couvelard, A | 1 |
Rebours, V | 1 |
Zappa, M | 1 |
Palazzo, M | 1 |
Maire, F | 1 |
Goujon, G | 1 |
Gillet, A | 1 |
Lévy, P | 1 |
Ruszniewski, P | 1 |
Fox, PA | 1 |
Goodyear, MD | 1 |
Willins, J | 1 |
Esthappan, J | 1 |
Rotman, M | 3 |
Parikh, PJ | 1 |
Dewas, CV | 1 |
Dalban, C | 1 |
Petitfils, A | 1 |
Peignaux, K | 1 |
Truc, G | 1 |
Martin, E | 1 |
Khoury, C | 1 |
Dewas, S | 1 |
John, M | 5 |
Palma, N | 1 |
Subramaniam, R | 1 |
Arnott, SJ | 1 |
Leslie, MD | 1 |
Morgan, DA | 1 |
Coucke, P | 1 |
Jager, JJ | 1 |
Van der Steen-Banasik, E | 1 |
Trivière, N | 1 |
Stüben, G | 1 |
Mercier, M | 1 |
Papagikos, M | 1 |
Skibber, J | 2 |
Janjan, NA | 1 |
Feig, B | 2 |
Hung, A | 2 |
Delclos, M | 2 |
Lin, E | 2 |
Cleary, K | 1 |
Crane, C | 1 |
Ballo, M | 1 |
Janjan, N | 1 |
Melcher, AA | 1 |
Vuong, T | 2 |
Devic, S | 2 |
Belliveau, P | 1 |
Muanza, T | 1 |
Hegyi, G | 1 |
Hildebrandt, B | 1 |
Gögler, H | 1 |
Ullrich, R | 1 |
Herrmann, R | 2 |
Riess, H | 1 |
Felix, R | 1 |
Deniaud-Alexandre, E | 3 |
Touboul, E | 4 |
Tiret, E | 4 |
Sezeur, A | 3 |
Houry, S | 3 |
Gallot, D | 3 |
Parc, R | 4 |
Huang, R | 1 |
Qu, SH | 1 |
Pène, F | 4 |
Schlienger, M | 5 |
Chauveinc, L | 1 |
Buthaud, X | 1 |
Falcou, MC | 1 |
Mosseri, V | 1 |
De la Rochefordière, A | 1 |
Pierga, JY | 1 |
Girodet, J | 1 |
Salmon, RJ | 1 |
O'Riordan, A | 1 |
Ong, C | 1 |
Pavlakis, N | 1 |
Veitch, P | 1 |
Hochwald, SN | 1 |
Riggs, CE | 1 |
Lerouge, D | 1 |
Laugier, A | 2 |
Nathanson, DR | 1 |
Bleday, R | 1 |
Hwang, JM | 1 |
Cosmatos, HA | 1 |
Wang, R | 1 |
Kaptein, JS | 1 |
Kagan, RA | 1 |
Hsiang, JY | 1 |
Tome, M | 1 |
Evans, TK | 1 |
Phillips, HA | 1 |
Takeno, A | 1 |
Masuda, N | 1 |
Kashiwazaki, M | 1 |
Takeda, Y | 2 |
Sawamura, T | 1 |
Morel, P | 2 |
Kouloulias, V | 1 |
Plataniotis, G | 1 |
Kouvaris, J | 1 |
Dardoufas, C | 1 |
Gennatas, C | 1 |
Uzunoglu, N | 1 |
Papavasiliou, C | 1 |
Vlahos, L | 1 |
Graham, BD | 1 |
Jetmore, AB | 1 |
Foote, JE | 1 |
Arnold, LK | 1 |
Ferrigno, R | 1 |
Nakamura, RA | 1 |
Dos Santos Novaes, PE | 1 |
Pellizzon, AC | 1 |
Maia, MA | 1 |
Fogarolli, RC | 1 |
Salvajoli, JV | 1 |
Filho, WJ | 1 |
Lopes, A | 1 |
Vorob'ëv, GI | 1 |
Odariuk, TS | 1 |
Orlova, LP | 1 |
Nechushkin, MI | 1 |
Rybakov, EG | 1 |
Charnley, N | 1 |
Choudhury, A | 1 |
Chesser, P | 1 |
Cooper, RA | 1 |
Blazy, A | 1 |
Hennequin, C | 1 |
Furco, A | 1 |
Gérard, L | 1 |
Lémann, M | 1 |
Maylin, C | 1 |
Grabenbauer, GG | 5 |
Kessler, H | 1 |
Sauer, R | 5 |
Hohenberger, W | 1 |
Schneider, IH | 3 |
Ambriz-González, G | 1 |
Escobedo-Zavala, LC | 1 |
Carrillo de la Mora, F | 1 |
Ortiz-Arriaga, A | 1 |
Cordero-Zamora, A | 1 |
Corona-Nakamura, A | 1 |
López Ramírez, MK | 1 |
Velázquez Ramírez, GA | 1 |
Milano, MT | 1 |
Farrey, KJ | 1 |
Rash, C | 1 |
Heimann, R | 1 |
Chetty, R | 1 |
Serra, S | 1 |
Hsieh, E | 1 |
Gurfinkel, R | 1 |
Walfisch, S | 1 |
Kim, YA | 1 |
Chung, HC | 2 |
Choi, HJ | 1 |
Rha, SY | 1 |
Seong, JS | 1 |
Jeung, HC | 1 |
Dwyer, MK | 1 |
Gebski, VJ | 1 |
Jayamohan, J | 1 |
Ibáñez, J | 1 |
Erro, JM | 1 |
Aranda, F | 1 |
Almendral, ML | 1 |
Valenti, C | 1 |
Echenique-Elizondo, M | 1 |
Lucato, LT | 1 |
McKinney, AM | 1 |
Short, J | 1 |
Teksam, M | 1 |
Truwit, CL | 1 |
Edelman, S | 1 |
Johnstone, PA | 1 |
Oehler-Jänne, C | 1 |
Seifert, B | 1 |
Saarilahti, K | 1 |
Arponen, P | 1 |
Vaalavirta, L | 1 |
Tenhunen, M | 1 |
Blomqvist, C | 1 |
Meyer, A | 1 |
Meier Zu Eissen, J | 1 |
Karstens, JH | 1 |
Bremer, M | 1 |
Sroa, N | 1 |
Bartholomew, DA | 1 |
Magro, CM | 1 |
Konstantinopoulos, PA | 1 |
Schlecht, HP | 1 |
Bryan, B | 1 |
Pantanowitz, L | 1 |
Dezube, BJ | 1 |
Hannoun, L | 1 |
Tytherleigh, MG | 1 |
Birtle, AJ | 1 |
Cohen, CE | 1 |
Livingstone, J | 1 |
Gilbert, J | 1 |
Kopek, N | 1 |
Ducruet, T | 1 |
Portelance, L | 1 |
Faria, S | 1 |
Bahoric, B | 1 |
Huang, K | 1 |
Haas-Kogan, D | 1 |
Weinberg, V | 2 |
Krieg, R | 3 |
Chen, YW | 1 |
Yen, SH | 1 |
Chen, SY | 1 |
Huang, PI | 1 |
Shiau, CY | 1 |
Liu, YM | 1 |
Lin, JK | 1 |
Wang, LW | 1 |
Hatfield, P | 1 |
Cooper, R | 1 |
Kindler, HL | 1 |
Cho, BC | 1 |
Ahn, JB | 1 |
Seong, J | 1 |
Roh, JK | 1 |
Kim, JH | 1 |
Sohn, JH | 1 |
Kim, NK | 1 |
Koh, DM | 1 |
Dzik-Jurasz, A | 1 |
O'Neill, B | 1 |
Husband, JE | 1 |
Brown, G | 1 |
Konski, A | 1 |
Garcia, M | 1 |
Pinover, W | 1 |
McDonald, AC | 1 |
Myint, S | 1 |
Samuel, L | 1 |
Meropol, NJ | 1 |
Niedzwiecki, D | 1 |
Shank, B | 2 |
Colacchio, TA | 1 |
Ellerton, J | 1 |
Valone, F | 1 |
Budinger, S | 1 |
Day, JM | 1 |
Hopkins, J | 1 |
Tepper, J | 1 |
Goldberg, RM | 1 |
Mackman, S | 1 |
Johnson, RO | 1 |
Michaelson, RA | 1 |
Magill, GB | 2 |
Quan, SH | 4 |
Leaming, RH | 2 |
Nikrui, M | 1 |
Stearns, MW | 1 |
Flam, MS | 3 |
Lovalvo, LJ | 2 |
Mills, RJ | 1 |
Ramalho, LD | 2 |
Prather, C | 1 |
Mowry, PA | 4 |
Morgan, DR | 1 |
Lau, BP | 1 |
Cummings, BJ | 10 |
Tiver, KW | 1 |
Langlands, AO | 1 |
Cummings, B | 1 |
Keane, T | 1 |
Thomas, G | 1 |
Harwood, A | 1 |
Rider, W | 1 |
Carey, RW | 1 |
Rider, WD | 2 |
Harwood, AR | 2 |
Keane, TJ | 4 |
Thomas, GM | 2 |
Erlichman, C | 1 |
Fine, S | 1 |
Sischy, B | 4 |
Remington, JH | 2 |
Hinson, EJ | 1 |
Sobel, SH | 2 |
Woll, JE | 1 |
Nigro, ND | 2 |
Seydel, HG | 3 |
Considine, B | 2 |
Vaitkevicius, VK | 2 |
Leichman, L | 2 |
Kinzie, JJ | 1 |
Weismann, K | 1 |
Kassis, V | 1 |
Wanebo, HJ | 2 |
Futrell, W | 1 |
Constable, W | 1 |
Zimm, S | 1 |
Wampler, GL | 1 |
Savlov, ED | 1 |
Marsh, RW | 1 |
Agaliotis, D | 1 |
Killeen, R | 1 |
Turk, PS | 1 |
Belliveau, JF | 1 |
Darnowski, JW | 1 |
Weinberg, MC | 1 |
Leenen, L | 1 |
de Gara, CJ | 1 |
Basrur, V | 1 |
Figueredo, A | 1 |
Goodyear, M | 1 |
Knight, P | 1 |
Ajao, OG | 1 |
Grillo, IA | 1 |
Malatani, T | 1 |
al Shehri, MY | 1 |
Shapiro, SJ | 2 |
Lacey, D | 1 |
Lopez, M | 1 |
Birnbaum, E | 1 |
Fleshman, J | 1 |
Fry, R | 1 |
Kodner, I | 1 |
Hashimoto, M | 1 |
Yamamoto, O | 1 |
Koh, J | 1 |
Sakai, S | 1 |
Shiraishi, T | 1 |
Chiba, Y | 1 |
Hosoda, Y | 1 |
Shirato, M | 1 |
Seki, T | 1 |
Basser, RL | 1 |
Smith, JG | 1 |
Worotniuk, V | 1 |
Guiney, MJ | 1 |
Beck, DE | 1 |
Karulf, RE | 1 |
Davidson, JA | 1 |
Witzigmann, H | 1 |
Sagasser, J | 1 |
Meyer, FM | 1 |
Witte, J | 1 |
Longo, WE | 1 |
Vernava, AM | 1 |
Wade, TP | 1 |
Coplin, MA | 1 |
Virgo, KS | 1 |
Johnson, FE | 1 |
Panzer, M | 1 |
Hültenschmidt, B | 1 |
Döker, R | 1 |
Huber, K | 1 |
Kuhne-Velte, HJ | 1 |
Hutter, M | 1 |
Rühl, U | 1 |
Wendt, T | 1 |
Chadha, M | 1 |
Rosenblatt, EA | 1 |
Malamud, S | 1 |
Pisch, J | 1 |
Berson, A | 1 |
Unverdorben, M | 1 |
Birkenhake, S | 1 |
Kunkel, B | 1 |
Dunst, J | 3 |
Holland, JM | 1 |
Swift, PS | 1 |
Smith, DE | 3 |
Shah, KH | 1 |
Frost, DB | 2 |
Latino, F | 1 |
Anderson, PJ | 1 |
Peddada, AV | 2 |
Kagan, AR | 2 |
Buffat, L | 1 |
Lefkopoulos, D | 1 |
Malafosse, M | 1 |
Wagner, JP | 1 |
Romestaing, P | 3 |
Rocher, FP | 1 |
Berger, C | 1 |
Trillet-Lenoir, V | 1 |
Fuhrman, GM | 1 |
Ota, DM | 1 |
Lipsett, J | 1 |
Leong, L | 1 |
Wagman, LD | 1 |
Terz, JJ | 1 |
Hübener, KH | 2 |
Jaiyesimi, IA | 1 |
Pazdur, R | 1 |
Kapp, KS | 2 |
Stuecklschweiger, G | 1 |
Berger, A | 2 |
Geyer, E | 2 |
Gall, FP | 2 |
Allal, A | 1 |
Kurtz, JM | 4 |
Pipard, G | 1 |
Marti, MC | 3 |
Miralbell, R | 1 |
Popowski, Y | 1 |
Egeli, R | 1 |
Tanum, G | 2 |
Karlsen, KO | 3 |
You, YT | 1 |
Wang, JY | 1 |
Changchien, CR | 1 |
Chen, JS | 1 |
Hsu, KC | 1 |
Tang, R | 1 |
Fan, HA | 1 |
O'Sullivan, B | 2 |
Wong, CS | 3 |
Catton, CN | 2 |
Roca, E | 1 |
Milano, MC | 1 |
Pennella, E | 1 |
Barugel, M | 1 |
Gualdrini, U | 1 |
Lumi, M | 1 |
Gonzalez, G | 1 |
Sardi, M | 1 |
Fleischer, I | 1 |
Graziano, A | 1 |
Lipsitz, SR | 2 |
Lefkopoulou, M | 1 |
Engstrom, PF | 1 |
Dayal, YY | 1 |
Cobau, CD | 1 |
Oken, MM | 1 |
Haller, DG | 1 |
Kaplan, EH | 1 |
Otteman, LA | 1 |
Schuchter, LM | 1 |
Sentenac, I | 1 |
Mahé, M | 1 |
Mishra, RC | 1 |
Senapati, S | 1 |
Sai, PL | 1 |
Pajak, TF | 2 |
Petrelli, N | 1 |
Doggett, S | 1 |
Quivey, J | 1 |
Kerman, H | 1 |
Coia, L | 1 |
Murray, K | 1 |
Bottomley, DM | 1 |
Aqel, N | 1 |
Selvaratnam, G | 1 |
Phillips, RH | 1 |
Doci, R | 2 |
Zucali, R | 2 |
La Monica, G | 1 |
Meroni, E | 1 |
Kenda, R | 1 |
Eboli, M | 1 |
Lozza, L | 1 |
Adamietz, IA | 1 |
Lorenz, M | 1 |
Staib-Sebler, E | 1 |
Böttcher, HD | 1 |
Bartelink, H | 1 |
Eschwege, F | 2 |
Rougier, P | 3 |
Gonzalez, DG | 1 |
van Glabbeke, M | 1 |
Pierart, M | 1 |
Seitz, JF | 2 |
Cvitkovic, F | 2 |
Nasca, S | 1 |
Lusinchi, A | 2 |
Debrigode, E | 1 |
Constantinou, EC | 1 |
Daly, W | 1 |
Fung, CY | 1 |
Kaufman, DS | 1 |
Valentini, V | 1 |
Morganti, AG | 1 |
Luzi, S | 1 |
Mantello, G | 1 |
Mantini, G | 1 |
Salvi, G | 1 |
Cellini, N | 1 |
Höcht, S | 1 |
Wiegel, T | 2 |
Kroesen, AJ | 1 |
Berdel, WE | 1 |
Runkel, N | 1 |
Hinkelbein, W | 1 |
Ayzac, L | 1 |
Hun, D | 1 |
Coquard, R | 1 |
Goldman, S | 2 |
Friberg, B | 1 |
Goldberg, ZI | 1 |
Chapman, WB | 2 |
Klamut, HJ | 1 |
Rauth, AM | 1 |
Obradovic, M | 1 |
Laurencet, F | 2 |
Spada, A | 1 |
Akpek, G | 1 |
Hartshorn, KL | 1 |
Bonin, SR | 1 |
Russell, AH | 1 |
Coia, LR | 1 |
Paris, KJ | 1 |
Sauter, ER | 1 |
Juturi, JV | 1 |
Francis, B | 1 |
Koontz, PW | 1 |
Wilkes, JD | 1 |
Hoffman, R | 1 |
Klencke, B | 1 |
Klas, JV | 1 |
Rothenberger, DA | 1 |
Wong, WD | 1 |
Madoff, RD | 1 |
Sprangers, MA | 1 |
Reymond, MA | 1 |
Tsao, MS | 1 |
Sharma, V | 1 |
Pintilie, M | 1 |
Faivre, C | 1 |
Mitry, E | 1 |
Lasser, P | 1 |
Elias, D | 1 |
Cleator, S | 1 |
Fife, K | 1 |
Phillips, R | 1 |
Manivit, P | 1 |
Polo, R | 1 |
Tabary, D | 1 |
Nabet, M | 1 |
Polo, M | 1 |
Adamy, M | 1 |
Rubini, B | 1 |
Fromaget, JM | 1 |
Chipponi, PN | 1 |
Untereiner, M | 1 |
Indinnimeo, M | 1 |
Cicchini, C | 1 |
Stazi, A | 1 |
Giarnieri, E | 1 |
Limiti, MR | 1 |
Ghini, C | 1 |
Vecchione, A | 1 |
Berney, CR | 1 |
Rohner, S | 1 |
Aapro, MS | 1 |
Alberto, P | 1 |
Brown, RS | 1 |
McCormack, M | 1 |
Lankester, KJ | 1 |
Spittle, MF | 1 |
Pehoushek, J | 1 |
Smith, KJ | 1 |
Gebhart, FH | 1 |
Oechs, AC | 1 |
Hebenstreit, J | 1 |
Stoeger, H | 1 |
Mitchell, SE | 1 |
Carroll, RR | 1 |
Sasaoka, M | 1 |
Fuwa, N | 1 |
Matsumoto, A | 1 |
Furutani, K | 1 |
Kamata, M | 1 |
Kodaira, T | 1 |
Khoubehi, B | 1 |
Schofield, A | 1 |
Slevin, ML | 1 |
Talbot, IC | 1 |
Giovannini, M | 2 |
Michel, P | 1 |
Luporsi, E | 1 |
Weber, DC | 1 |
Vordermark, D | 2 |
Flentje, M | 2 |
Sailer, M | 2 |
Kölbl, O | 2 |
Thiede, A | 1 |
Grieger, J | 1 |
Lachmann, R | 1 |
Bohrer, M | 1 |
Tiefenbacher, U | 1 |
Haberman, HF | 1 |
Goodall, J | 1 |
Llewellyn, M | 1 |
Bruckner, HW | 1 |
Spigelman, MK | 1 |
Mandel, E | 1 |
Cohen, C | 1 |
Deppe, G | 1 |
Turell, R | 1 |
Schiavone, J | 1 |
Kolleg, MK | 1 |
Moore, GE | 1 |
Norton, LW | 1 |
Meiselbaugh, DM | 1 |
Hajdu, SI | 1 |
Sturm, JT | 1 |
Christenson, CE | 1 |
Uecker, JH | 1 |
Perry, JF | 1 |
Newman, HK | 1 |
Reck, T | 1 |
Köckerling, F | 1 |
Kaigas, M | 1 |
Norum, J | 1 |
Wist, E | 1 |
Sfedj, D | 1 |
Houvenaeghel, G | 1 |
Bombelli, L | 1 |
Montalto, F | 1 |
Lamonica, G | 1 |
Krebs, HB | 1 |
Lopez, MJ | 1 |
Fry, RD | 1 |
Halverson, JD | 1 |
Monafo, WW | 1 |
Epperson, WJ | 1 |
Bugat, R | 1 |
Sommer, K | 1 |
Brockmann, WP | 1 |
Krüll, A | 1 |
Birk, S | 1 |
Lange, CS | 1 |
Papillon, J | 1 |
Thirlby, RC | 1 |
Hammer, CJ | 1 |
Galagan, KA | 1 |
Travaglini, JJ | 1 |
Picozzi, VJ | 1 |
Kuzel, T | 1 |
Esparaz, B | 1 |
Green, D | 1 |
Kies, M | 1 |
Hughes, L | 1 |
Brock, W | 1 |
Mieno, K | 1 |
Satoi, Y | 1 |
Amino, K | 1 |
Miura, S | 1 |
Shikata, J | 1 |
Oberlin, P | 1 |
Crickx, B | 1 |
Picard, C | 1 |
Benhamou, G | 1 |
Vilotte, J | 1 |
Vissuzaine, C | 1 |
Bilbault, P | 1 |
Belaïch, S | 1 |
Habr-Gama, A | 1 |
da Silva e Sousa Júnior, AH | 1 |
Nadalin, W | 1 |
Gansl, R | 1 |
da Silva, JH | 1 |
Pinotti, HW | 1 |
Fosså, SD | 2 |
Flokkmann, A | 2 |
Guldvog, I | 1 |
Haffner, J | 1 |
Wolf, N | 2 |
San Martín, S | 1 |
Armando, S | 1 |
Arraztoa, J | 1 |
Morales, Y | 1 |
Carrasco, CH | 1 |
Jackson, DE | 1 |
Wallace, S | 1 |
Hughes, LL | 1 |
Delclos, L | 1 |
Martin, RG | 1 |
Doggett, RL | 1 |
Krall, JM | 1 |
Taylor, DG | 1 |
Sause, WT | 1 |
Lipsett, JA | 1 |
Tjandra, J | 1 |
Sillman, FH | 1 |
Sedlis, A | 1 |
Boyce, JG | 1 |
Muff, NS | 1 |
Shetabi, H | 1 |
Wittlinger, P | 1 |
Podolsky, W | 1 |
Padmanabhan, A | 1 |
Dobrowsky, W | 1 |
John, MJ | 2 |
Lovalvo, L | 1 |
Secco, GB | 1 |
Sertoli, MR | 1 |
Scarpati, D | 1 |
Marino, G | 1 |
Fardelli, R | 1 |
Nobile, MT | 1 |
Wade, J | 1 |
Reichard, U | 1 |
Denecke, H | 1 |
Roloff, R | 1 |
Peppe, H | 1 |
Bianchi, C | 1 |
Bianchi, O | 1 |
Stringa, S | 1 |
Schmidt, KU | 1 |
Wiskemann, A | 1 |
Mensing, H | 1 |
Khater, R | 1 |
Frenay, M | 1 |
Bourry, J | 1 |
Milano, G | 1 |
Namer, M | 1 |
Nigro, N | 1 |
Buroker, T | 1 |
Bradley, G | 1 |
Olchowski, S | 1 |
Cummings, G | 1 |
Leichman, C | 1 |
Smith, RA | 1 |
Stubblefield, GC | 1 |
Brock, DT | 1 |
Reagan, MT | 1 |
Greenall, MJ | 1 |
Urmacher, C | 1 |
DeCosse, JJ | 1 |
Fischerman, K | 1 |
Briand, P | 1 |
Olsen, J | 1 |
Nielsen, OV | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.[NCT02402842] | Phase 2 | 70 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA Study[NCT04894370] | Phase 2 | 34 participants (Anticipated) | Interventional | 2022-06-09 | Recruiting | ||
A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma[NCT03519295] | Phase 2 | 99 participants (Anticipated) | Interventional | 2018-07-22 | Active, not recruiting | ||
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
Immunomonitoring and Biomarker Research Based on Tumor and Blood Samples in Patients With Squamous Cell Anal Carcinoma[NCT03942900] | 0 participants (Actual) | Observational | 2020-04-01 | Withdrawn (stopped due to Study not submitted to regulatory authorities) | |||
Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy[NCT02369939] | Phase 3 | 118 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal[NCT01858025] | Early Phase 1 | 25 participants (Actual) | Interventional | 2013-07-31 | Active, not recruiting | ||
Efficacy and Safety of Topical Trichloroacetic Acid vs. Electrocautery for the Treatment of Anal Intraepithelial Neoplasia in HIV-positive Patients (TECAIN) - a Randomized Controlled Trial[NCT02615860] | 560 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851] | Phase 2 | 16 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | ||
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607] | Phase 2 | 75 participants (Anticipated) | Interventional | 2019-03-13 | Recruiting | ||
Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal[NCT05019235] | 154 participants (Actual) | Observational | 2021-08-05 | Active, not recruiting | |||
Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus[NCT05201105] | 43 participants (Actual) | Observational | 2021-10-15 | Completed | |||
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0[NCT01621217] | Phase 1 | 21 participants (Anticipated) | Interventional | 2012-06-30 | Completed | ||
Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma[NCT00324415] | Phase 2 | 45 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal[NCT00003596] | Phase 3 | 682 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study[NCT00068744] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2003-07-31 | Terminated (stopped due to low accrual) | ||
Observational Study of Functional Outcomes After Chemoradiotherapy for Squamous Cell Cancer of the Anus[NCT01853059] | 176 participants (Anticipated) | Observational | 2013-10-31 | Not yet recruiting | |||
A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in absolute CD4 counts from start of treatment to 1 year after completion of study treatment (NCT00324415)
Timeframe: 1 year following treatment discontinuation
Intervention | cells/mm3 (Median) |
---|---|
Combined Modality Therapy | 102 |
Percentage of participants who are alive and have not had a colostomy (NCT00324415)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Combined Modality Therapy | 92.4 |
Incidence of opportunistic illnesses, including the development of AIDS during and for 1 year after completion of study treatment (NCT00324415)
Timeframe: 1 year following treatment discontinuation
Intervention | participants (Number) |
---|---|
Combined Modality Therapy | 4 |
Patients will be classified into two groups for purposes of primary endpoint analysis: failure or no failure at 3 years (in the primary analysis, patients lost to follow-up prior to 3 years will be considered failures). For the secondary endpoint of objective response, patients will be classified as responders (NCT00324415)
Timeframe: 3 years following treatment discontinuation
Intervention | participants (Number) |
---|---|
Combined Modality Therapy | 23 |
Number of participants with complete and partial responses based on the RECIST criteria (NCT00324415)
Timeframe: 3 years following treatment discontinuation
Intervention | participants (Number) |
---|---|
Combined Modality Therapy | 30 |
Percentage of participants who are alive at one year (NCT00324415)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Combined Modality Therapy | 92.8 |
Progression-free survival at 1 year is the percentage of patients who are alive and have not experienced progressive disease, defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, or the appearance of one or more new lesions. (NCT00324415)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Combined Modality Therapy | 87.3 |
EORTC QLQ-C30 Global Score at 1 year. The EORTC QLQ-C30 is a validated questionnaire that evaluates quality of life. The global score is an overall score for quality of life that ranges from 0 to 100. Higher scores indicate between quality of life (NCT00324415)
Timeframe: 1 year
Intervention | units on a scale (Mean) |
---|---|
Combined Modality Therapy | 78.9 |
Percentage of participants who are alive and have not experienced progressive disease and have not relapsed (NCT00324415)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Combined Modality Therapy | 83.1 |
Delayed toxicities are defined as toxicities that occur over 90 days following treatment completion (NCT00324415)
Timeframe: 90 days following treatment discontinuation
Intervention | events (Number) |
---|---|
Combined Modality Therapy | 5 |
41 reviews available for fluorouracil and Anal Cancer
Article | Year |
---|---|
[Anal cancer: Focus on current treatment and future perspective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Comparison of intravenous 5-Fluorouracil with Oral Capecitabine in the Treatment of Anal Squamous Cell Carcinoma Using Modern Radiation Techniques.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce | 2023 |
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
Topics: Anus Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as | 2019 |
[Squamous cell anal carcinoma. What's next ?]
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Ca | 2021 |
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorouracil; Humans; Rectal Neoplasms | 2021 |
Randomized Clinical Trials in Localized Anal Cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 2017 |
Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Diagnostic Imagin | 2019 |
Chemoradiotherapy for anal cancer: are we as good as we think?
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Thera | 2019 |
[Brachytherapy for anal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous C | 2013 |
Anal squamous intraepithelial neoplasia.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Antimetabolites, Antineoplastic; A | 2013 |
Anal cancer treatment: current status and future perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; C | 2015 |
Advances in the Management of Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Cisplatin; Female; Flu | 2016 |
Treatment of the Primary Tumor in Anal Canal Cancers.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2017 |
Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2017 |
Capecitabine in locally advanced anal cancer, do we need randomised evidence?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cap | 2017 |
Current management of anal canal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fluoroura | 2009 |
Intensity-modulated radiation therapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Combined Modality Therapy | 2009 |
Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fluoroura | 2010 |
[Radiochemotherapy for locally advanced anal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Combined-modality treatment for anal cancer: current strategies and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C | 2010 |
[Management of anal canal carcinoma].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2011 |
[Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera | 2012 |
[A case of perianal squamous cell carcinoma attaining a complete response over five years with chemoradiotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anus Neoplasms; Biopsy; Carcinoma, Squ | 2011 |
Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness.
Topics: Adult; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anus Neoplasms; Cido | 2012 |
Squamous cell carcinoma of the anal margin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2004 |
[Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2004 |
Chemotherapeutic options in the management of anal cancer.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; HIV Se | 2004 |
Lipodermatosclerosis as a form of vascular compromise-associated radiation recall dermatitis: case report and a review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2006 |
Current treatment for localized anal carcinoma.
Topics: Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Mi | 2007 |
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C | 1984 |
Combination therapy for epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
[Cancer of the anal canal].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1990 |
Anal canal cancer: current treatment and results.
Topics: Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1996 |
[Chemoradiotherapy in treatment of cancer of the anal canal].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, | 1998 |
Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1999 |
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 1999 |
[Radiochemotherapy in anal canal epidermoid cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2000 |
Concomitant radiotherapy and chemotherapy for anal cancer.
Topics: Anus Neoplasms; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Mitomycins | 1992 |
A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil.
Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anal Canal; Anus Neoplasms; Carc | 1985 |
76 trials available for fluorouracil and Anal Cancer
Article | Year |
---|---|
Capecitabine in the treatment of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce | 2022 |
Pilot trial of topical MTS‑01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage I‑III carcinoma of the anal canal.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Dermatitis; Fluorouracil; H | 2022 |
A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2023 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Anti-Telomerase CD4
Topics: Adaptive Immunity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; A | 2020 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 2018 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.
Topics: Aminoquinolines; Anus Neoplasms; Carcinoma in Situ; Electrocoagulation; Fluorouracil; HIV; HIV Infec | 2013 |
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
[Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98-11 trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; Diseas | 2013 |
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2013 |
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Anus Neoplasms; Cetuximab; Chemoradiotherapy; Cispla | 2013 |
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 2013 |
Impact of advancing age on treatment and outcomes in anal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2014 |
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2014 |
Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Area Under Curve; Carcinoma, | 2016 |
The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2015 |
Phase II study of computed tomography-guided (125)I-seed implantation plus chemotherapy for locally recurrent rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Camptoth | 2016 |
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetu | 2015 |
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce | 2016 |
Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradioth | 2016 |
Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2016 |
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2017 |
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2017 |
Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2017 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2017 |
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2009 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma; Fluorouracil; Follow-Up S | 2010 |
"Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2011 |
Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2011 |
Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Benzodiazepines; Chemor | 2011 |
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2012 |
Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Female; Flu | 2013 |
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2012 |
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastr
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Thera | 2003 |
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2003 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
[Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2003 |
[Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2003 |
Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Dia | 2005 |
Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach.
Topics: Administration, Topical; Adult; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Biopsy; Bowen | 2005 |
Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Sq | 2005 |
Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Anus Neoplasms; Combined | 2006 |
Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisp | 2008 |
Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colo | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2008 |
[Treatment of condyloma acuminatum with 0.5% 5-fluorouracil-solution, A double-blind clinical trial].
Topics: Administration, Topical; Adolescent; Adult; Anus Neoplasms; Clinical Trials as Topic; Condylomata Ac | 1982 |
Conservative management of squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Combination therapy for epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
Mitomycin in anal canal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anu | 1993 |
[Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1995 |
Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Combined Modality Therapy | 1996 |
Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colostomy; Combined Modality Therapy | 1997 |
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colostomy; Combined Modality Therapy | 1997 |
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colostomy; Combined Modality Therapy | 1997 |
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colostomy; Combined Modality Therapy | 1997 |
Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; | 1997 |
Is chemoradiation feasible in elderly patients? A study of 17 patients with anorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Mo | 1997 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
[Chemoradiotherapy in treatment of cancer of the anal canal].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, | 1998 |
Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1999 |
Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Comb | 1999 |
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo | 2000 |
High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2001 |
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera | 2001 |
Condyloma. A new epidemic.
Topics: Antineoplastic Agents; Anus Neoplasms; Colorado; Condylomata Acuminata; Cryosurgery; Dinitrochlorobe | 1978 |
311 other studies available for fluorouracil and Anal Cancer
Article | Year |
---|---|
Dosimetric and Clinical Predictors for Acute and Late Gastrointestinal Toxicity Following Chemoradiotherapy of Locally Advanced Anal Cancer.
Topics: Anus Neoplasms; Chemoradiotherapy; Fluorouracil; Humans; Radiotherapy, Intensity-Modulated; Retrospe | 2022 |
Molecular and genomic characterisation of a panel of human anal cancer cell lines.
Topics: Animals; Anus Neoplasms; B7-H1 Antigen; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2021 |
Current treatment and future directions in the management of anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Long-term survival after treatment for primary anal cancer- results from the Swedish national ANCA cohort study.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2022 |
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2022 |
New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2022 |
Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
Topics: Anal Canal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2023 |
Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2023 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Topics: Anus Neoplasms; Fluorouracil; Humans; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, In | 2022 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
[A Case of Long-Term Survival with S-1/Cisplatin for Liver Hilum Lymph Node Metastasis of Anal Canal Squamous Cell Carcinoma after Chemoradiotherapy].
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamou | 2022 |
Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2023 |
Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Disea | 2023 |
Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer.
Topics: Anus Neoplasms; Capecitabine; Cohort Studies; Fluorouracil; Humans; Mitomycin; Prospective Studies; | 2023 |
Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2019 |
Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2019 |
Sweet syndrome and erythema nodosum in a case of anal canal cancer during concomitant radiochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Erythema Nodosum; | 2019 |
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2020 |
Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2020 |
Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2020 |
Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Fluorouracil; Hum | 2020 |
Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2020 |
Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2020 |
How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial.
Topics: Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Paclitaxel | 2020 |
Reply to S. Kim et al.
Topics: Anus Neoplasms; Carboplatin; Cisplatin; Fluorouracil; Humans; Paclitaxel | 2020 |
Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2021 |
Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2021 |
Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Co | 2017 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurr | 2017 |
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone | 2017 |
Chemotherapy, "Lighting the Fire" or "Releasing the Brakes" in Metastatic Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Catheter A | 2017 |
[A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Che | 2017 |
Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Chemoradioth | 2017 |
Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Female; Fluorouracil; Humans; Hypert | 2017 |
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2018 |
Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer.
Topics: Adult; Aged; Anus Neoplasms; Bacterial Vaccines; Chemoradiotherapy; Female; Fluorouracil; Humans; Im | 2018 |
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Topics: Adenocarcinoma; Aged; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Coh | 2018 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Neop | 2018 |
Treatment Effects Can Mimic Recurrent Extramammary Paget Disease in Perianal Skin.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Anus Neoplasms; Biomarkers, Tumor; Biops | 2018 |
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An | 2018 |
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Chemoradiotherap | 2018 |
Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2018 |
FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2019 |
Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
Topics: Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Databases, Fac | 2018 |
Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiot | 2019 |
Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Ca | 2018 |
Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2019 |
[Outcomes of Anal Squamous Cell Carcinoma Treated with Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2018 |
[A Case of Colostomy-Free and Long-Term Survival with 5-FU/CDDP for Local Recurrence of Anal Cancer after Chemoradiation Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Colostomy; Female | 2019 |
Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamou | 2019 |
Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication.
Topics: Aged; Anaphylaxis; Anus Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Colon, Si | 2019 |
One step towards standardised management of anal dysplasia.
Topics: Aminoquinolines; Anus Neoplasms; Electrocoagulation; Fluorouracil; Homosexuality, Male; Humans; Imiq | 2013 |
RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction?
Topics: Anal Canal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2013 |
Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiother | 2013 |
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2013 |
Anal carcinoma: surgery does not influence prognosis when performed prior to concurrent radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Comb | 2013 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free | 2013 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
Combination chemotherapy for metastatic extramammary Paget disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Neopla | 2014 |
Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Results of age-dependent anal canal cancer treatment: a single centre retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2014 |
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2014 |
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Axons; Carcinoma, Squamous Cell; Class I Phosphatidylin | 2014 |
External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Cisplatin; Combined Modality Therapy; Female; Fluoro | 2014 |
Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Combined Modality Therapy; Fe | 2014 |
Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carcinoma, Squamo | 2015 |
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carb | 2014 |
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2014 |
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2015 |
Review of anal cancer patients at the Ottawa hospital.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2015 |
Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 2015 |
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2015 |
Perianal infection of highly oncogenic human papilloma virus: how to prevent from cancer? Case report.
Topics: Anal Canal; Anus Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hemorrhoidectomy; He | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptotheci | 2017 |
French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2015 |
Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Australia; Carcinoma, S | 2015 |
Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclin- | 2015 |
Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus | 2015 |
[Results of complex treatment of patients with squamous cell carcinoma of the anal canal using advanced radiotherapy technologies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2015 |
[Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Che | 2016 |
Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cohort Studies; | 2016 |
Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2017 |
Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil.
Topics: Acute Disease; Anus Neoplasms; Carcinoma, Squamous Cell; Coronary Angiography; Electrocardiography; | 2016 |
Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2016 |
Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Caspase 8; | 2016 |
Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level.
Topics: Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carci | 2016 |
Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Anus Neoplasms; Dihydrouracil Dehydrogen | 2016 |
Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; Chemoradio | 2016 |
The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
Topics: Acetates; Antimetabolites, Antineoplastic; Anus Neoplasms; Depression; Drug Overdose; Emergency Medi | 2017 |
Cetuximab chemoradiotherapy in HIV-associated anal cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms | 2017 |
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2017 |
Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Cisplatin; F | 2008 |
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Colostomy; Combine | 2009 |
Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2009 |
Anal cancer chemoirradiation with curative intent - a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2009 |
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carci | 2010 |
Treatment options in metastatic squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; | 2008 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Comb | 2009 |
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy | 2010 |
Anal cancer: one step forward--two steps sideways!
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Clinical T | 2009 |
Successful treatment of a large Buschke-Lowenstein tumour with chemo-radiotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Anus Neoplasms; Cisplatin; Combined Modality | 2009 |
Commentary: Anal cancer - the benefits of evidence-based treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2009 |
[A case of anal canal carcinoma with systemic lymph node metastases successfully treated by bevacizumab+mFOLFOX6 therapy].
Topics: Anal Canal; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2009 |
Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemothera | 2007 |
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
Anal cancer with cerebral metastasis: a case report.
Topics: Antineoplastic Agents; Anus Neoplasms; Brain Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Comb | 2011 |
Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
Topics: Administration, Topical; Adult; Aged; AIDS-Related Opportunistic Infections; Antimetabolites, Antine | 2010 |
Squamous cell carcinoma of the anal margin: the university of Florida experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Topics: Antineoplastic Agents; Anus Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therap | 2010 |
[mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow Ne | 2010 |
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squam | 2012 |
[Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas].
Topics: Administration, Oral; Aged; Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic | 2010 |
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; | 2011 |
[Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2010 |
[A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2011 |
Quality of life outcomes in patients with anal cancer after combined radiochemotherapy.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anus Neoplasms; Chemotherapy, Adjuvant; | 2011 |
Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; CD4 Lymph | 2012 |
Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Combined Mo | 2012 |
Twenty-five-year experience with radical chemoradiation for anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2012 |
Primary Signet Ring Cell Anal Adenocarcinoma.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Signet Ring Cell; Col | 2012 |
Endobronchial metastases of anal canal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bronchial Neoplasms; Bronchopneumoni | 2012 |
Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2012 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progressi | 2011 |
[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node].
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecita | 2011 |
Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.
Topics: Aged; Anus Neoplasms; Cadherins; Carcinoma, Squamous Cell; Combined Modality Therapy; Desmocollins; | 2012 |
Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of rad
Topics: Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Fluorouracil; Hu | 2012 |
Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Bone Marrow; Capeci | 2012 |
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2012 |
Role of positron emission tomography-computed tomography in the management of anal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2012 |
Treatment of carcinoma of the anal canal at Groote Schuur Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2012 |
Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Topics: Adipose Tissue; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2013 |
High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy.
Topics: Antineoplastic Agents; Anus Neoplasms; Chemoradiotherapy; Female; Fluorouracil; Humans; Immunohistoc | 2012 |
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2012 |
Self-assessment quiz: answers, critiques, and references.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 2012 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap | 2012 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma | 2012 |
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2012 |
Ten-year results of chemoradiation for anal cancer: focus on late morbidity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Comb | 1996 |
Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Endometrial Neopla | 2002 |
Chemoradiation for adenocarcinoma of the anus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq | 2003 |
Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2003 |
Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Dise | 2003 |
Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Blue fingers.
Topics: Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fingers; Fl | 2003 |
[Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience].
Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Ch | 2003 |
Recent clinical trials summary.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anus Neoplasms; Brachytherapy; Female; | 2004 |
Bilateral leg amputation following chemoradiation for squamous carcinoma of the anus.
Topics: Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2004 |
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2005 |
[Prognosis of epidermoid anal carcinoma regression after conservative treatment].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2004 |
Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Anus Ne | 2005 |
Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2005 |
Buschke-Löwenstein tumor in childhood: a case report.
Topics: Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Verrucous; Child; Condylomata Acuminata; | 2005 |
Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Fem | 2005 |
Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant.
Topics: Anal Canal; Antibiotics, Antineoplastic; Antigens, CD20; Antimetabolites, Antineoplastic; Antineopla | 2005 |
Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy, Needle; Carcinoma, Squamous | 2005 |
[Chemoradiotherapy and anal canal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Clinical Trials, Phase III as Topic; | 2005 |
Intermediate dose 5-fluorouracil-induced encephalopathy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasm | 2006 |
The bottom line: outcomes after conservation treatment in anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2006 |
[Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant chemoradiotherapy and laparoscopy-assisted abdominoperineal amputation].
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Anus Neoplasms; Chemotherapy, Adjuvant; C | 2006 |
Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity.
Topics: Adult; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Corpus Callosum; F | 2006 |
Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cis | 2006 |
Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Fema | 2006 |
Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2006 |
HIV-associated anal squamous cell cancer: an otherwise preventable disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Anus Neoplasm | 2006 |
[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2006 |
Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Combined Modality T | 2007 |
Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Thera | 2007 |
Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Thera | 2008 |
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2007 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anus N | 2008 |
Infusion of 5-fluorouracil into the hypogastric artery for massive anal carcinoma.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Fluorouracil; Humans; Infusions, Parenteral; | 1967 |
Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1983 |
Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Drug Th | 1983 |
Carcinoma of the anal canal--radiation or radiation plus chemotherapy?
Topics: Anus Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycin; Mitomycins; Radiotherapy | 1983 |
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Car | 1984 |
Regression of pulmonary metastases from cloacogenic carcinoma after cis-platinum/5-fluorouracil treatment.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transit | 1984 |
Combined radical radiation therapy and chemotherapy for primary squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1982 |
Definitive treatment of anal-canal carcinoma by means of radiation therapy and chemotherapy.
Topics: Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1982 |
Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Ag | 1983 |
Radiation therapy and chemotherapy in the treatment of primary anal canal carcinoma.
Topics: Anus Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Male; Mitomycins | 1983 |
Multimodality approach to surgical management of locally advanced epidermoid carcinoma of the anorectum.
Topics: Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lymphat | 1981 |
Response of metastatic cloacogenic carcinoma to treatment with semustine.
Topics: Anus Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Fluorouracil; Hu | 1981 |
Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy, radiotherapy and operation.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; | 1980 |
Combined treatment of squamous cell carcinoma of the anal canal: radical radiation therapy with 5-fluorouracil and mitomycin-C, a preliminary report.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1980 |
Treatment of invasive squamous cell carcinoma complicating anal Buschke-Löwenstein tumor: a case history.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous C | 1995 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 1993 |
The influence of age on the management of anal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamo | 1995 |
Colo-rectal carcinoma in a tropical African population: an overview report.
Topics: Adenocarcinoma; Administration, Rectal; Adolescent; Adult; Aged; Anus Neoplasms; Ascites; Colonic Ne | 1994 |
Carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1995 |
[A case of fistula-cancer response to arterial chemoembolization].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoembolization, T | 1994 |
Prevention of 5 fluorouracil associated cardiotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Female; Fluorouracil; Heart; Humans; Powders; Uterin | 1994 |
[Therapy of anal cancer].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therap | 1994 |
Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 1994 |
[The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Squamous-cell carcinoma of the anus in HIV-positive patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anu | 1994 |
[Extended reversible global left ventricular contraction dysfunction with symptomless coronary system as effect of cytostatic therapy with 5-fluorouracil].
Topics: Anus Neoplasms; Combined Modality Therapy; Coronary Angiography; Coronary Vasospasm; Diagnosis, Diff | 1994 |
Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neop | 1994 |
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1994 |
Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1994 |
Radiation therapy in the conservative treatment of carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1994 |
Laparoscopic intestinal stomas.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy; | 1994 |
Carcinoma of the anus treated with primary radiation therapy and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Clinical P | 1993 |
[Radiochemotherapy in anal carcinoma: radiation plus 5-FU with and without long-term cisplatin infusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Combined Modality Therapy | 1993 |
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 1993 |
Epidermoid carcinoma of the anal canal: treatment by combined radiation and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1993 |
Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Fol | 1993 |
Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
An alternative treatment of anal squamous cell carcinoma: combined radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1993 |
Treatment of relapsing anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Comb | 1995 |
Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1996 |
Epidermoid anal cancer in HIV infected patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1996 |
[Outcome of simultaneous radiochemotherapy of anal carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1997 |
Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1997 |
Time-dose considerations in the treatment of anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Anus Neoplasms; Combine | 1997 |
Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Dr | 1997 |
Induction chemotherapy and radiotherapy in loco-regionally advanced epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carb | 1998 |
Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fluoroura | 1998 |
Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1999 |
Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Car | 1999 |
The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; CD4 Lymphocyte Count; Cisplatin; Com | 1999 |
Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
Treatment of HIV-associated invasive anal cancer with combined chemoradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fl | 2000 |
[Initial locoregional chemotherapy in recurrent and locoregional advanced or inoperable stages of pelvic uterine and anorectal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Cisplatin; D | 1995 |
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis?
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combin | 2000 |
Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil.
Topics: Anus Neoplasms; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Neop | 2000 |
Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man.
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma in Situ; | 2001 |
Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2001 |
Squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2001 |
[Two cases of squamous cell carcinoma of the anal canal treated with chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 2001 |
Metastatic in-situ perianal Paget's disease.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Fluorourac | 2001 |
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2001 |
Impaired sphincter function and good quality of life in anal carcinoma patients after radiotherapy: a paradox?
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colostomy; Combined Moda | 2002 |
Radiochemotherapy for anal carcinoma - effectivity and late toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2002 |
Extramammary Paget's disease.
Topics: Aged; Anus Neoplasms; Fluorouracil; Genital Neoplasms, Male; Humans; Male; Paget Disease, Extramamma | 1978 |
Carcinoma of the anus treated with a combination of radiotherapy and chemotherapy.
Topics: Adult; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1979 |
[Practice in the treatment of rectal carcinoma. Recommendations of the Deutschen Gesellschaft für Chirurgie].
Topics: Anus Neoplasms; Female; Fluorouracil; Germany, West; Humans; Intestinal Polyps; Male; Neoplasm Metas | 1977 |
Multidisciplinary preoperative approach to the management of epidermoid carcinoma of the anus and anorectum.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Ag | 1978 |
Squamous-cell carcinoma of the anus arising in a giant condyloma acuminatum: report of a case.
Topics: Administration, Topical; Anal Canal; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous Cell; Condyl | 1975 |
Multi-modality therapy for epidermoid carcinoma of the anus.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle | 1976 |
Combined radiation and chemotherapy for epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorourac | 1992 |
Induction chemotherapy with carboplatin and 5-fluorouracil in combination with radiotherapy in loco-regionally advanced epidermoid carcinoma of the anus--preliminary results.
Topics: Adult; Aged; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; | 1992 |
[Treatment of advanced anal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 1992 |
[Transanorectal ultrasonography in the evaluation of extension and the monitoring of epidermoid cancers of the anus treated by radiation or chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1992 |
Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
Treatment of genital condylomata with topical 5-fluorouracil.
Topics: Administration, Topical; Anus Neoplasms; Combined Modality Therapy; Condylomata Acuminata; Female; F | 1991 |
Squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1991 |
[Radiotherapy of epidermoid cancers of the anal canal].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Carcinoma, Squamous Cell; | 1991 |
Androscopy for anogenital HPV.
Topics: Acetates; Acetic Acid; Adult; Anus Neoplasms; Cryosurgery; Female; Fluorouracil; Genital Neoplasms, | 1991 |
[Carcinomas of the anal canal. Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Clinical Protocols; Combined M | 1991 |
The force of change in the management of squamous-cell cancer of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
[The therapeutic results and early and late toxicities of the treatment of anal canal carcinoma by radiotherapy or chemoradiotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combine | 1991 |
Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
Anal cancer: radiation and concomitant continuous infusion chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fluoroura | 1991 |
Effectiveness of combined radio-chemotherapy in the management of epidermoid carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1990 |
Perianal Paget's disease: successful treatment with combined chemoradiotherapy. Report of a case.
Topics: Aged; Anus Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Male; Mitomycin; Mitomycins; | 1990 |
Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Fibrinogen; Fibrinopeptide A; Fluo | 1990 |
Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer.
Topics: Anus Neoplasms; Combined Modality Therapy; Fluorouracil; Humans | 1990 |
[Current status of chemotherapy for colonic, rectal and anal carcinoma].
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colonic Neoplasms; Combi | 1990 |
[Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Carcinoma, Squamous Cell; | 1989 |
[Buschke-Lowenstein tumor of the anal area].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Cisplatin; Condylomata Ac | 1989 |
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1989 |
Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S | 1989 |
[Anal canal carcinoma: diagnosis--therapy--prognosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Female; F | 1989 |
[Anal neoplasms. Treatment with radiotherapy and exclusive chemotherapy].
Topics: Aged; Anus Neoplasms; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Midd | 1989 |
Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1989 |
Radiotherapy for anal cancer: experience from 1979-1987.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce | 1989 |
Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cobalt Radioisot | 1989 |
Perianal Paget's disease. Report of three cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anus Neoplasms; Female; Fluorouracil; Humans; Male; Neoplas | 1988 |
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
[Combined radio- and chemotherapy of anal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Colo | 1986 |
[Radiotherapy and chemotherapy in anal carcinoma].
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorourac | 1987 |
Feasibility of non-surgical definitive management of anal canal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
Preoperative chemotherapy and radiotherapy in the management of epidermoid carcinoma of the anal canal.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1987 |
Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1987 |
Preoperative radio-chemotherapy in anal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Basal Cell; Carcino | 1988 |
[Cutaneous metastasis of a cloacogenic tumor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transitional Cell; | 1987 |
[Etretinate and 5-fluorouracil in intra-anal Bowen's disease].
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bowen's Disease; | 1986 |
Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1986 |
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1985 |
Treatment of anal canal carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachyt | 1985 |
The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum.
Topics: Aged; Antibiotics, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Thera | 1985 |
Anorectal squamous cell carcinoma at Mississippi Baptist Medical Center: results of the last five years of the Nigro schedule.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 1985 |
Treatment of epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1985 |
Intra-arterial combined cancer chemotherapy in technically inoperable carcinoma of the anus and rectum.
Topics: Aged; Animals; Anus Neoplasms; Daunorubicin; Depression, Chemical; Dogs; Drug Therapy, Combination; | 1974 |